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Abstract 
Background and Aims 
Cystic fibrosis (CF) is characterised by repeated bacterial respiratory infections and progressive lung 
disease. While Pseudomonas aeruginosa is the most prevalent organism recovered from the 
respiratory secretions of people with CF, other species including Staphylococcus aureus, 
Stenotrophomonas maltophilia, Achromobacter species, Burkholderia cepacia complex species, and 
Mycobacterium abscessus may also be detected. The majority of these pathogens are found in the 
natural environment and the identification of genetically diverse bacterial strains infecting people 
with CF would suggest that this is the most common acquisition source. However, epidemiological 
studies have demonstrated that some people with CF may harbour genetically indistinguishable 
(shared) strains of organisms. Common environmental reservoirs have not been identified for many 
shared strains, suggesting that person-to-person transmission may be a method of acquisition, 
although the exact mechanisms involved are unclear. The airborne route, involving inhalation of 
microbe-containing droplet nuclei, has been speculated as a possible transmission pathway.  
Previous studies have demonstrated that people with CF can generate droplet nuclei containing  
P. aeruginosa, which can survive for up to 45-minutes and can travel up to 4-metres from their source 
and therefore potentially capable of airborne transmission. The survival of other common CF 
pathogens over distance and time is not known. Recent updates to CF infection control guidelines in 
some countries recommend the use of a surgical face mask for people with CF to minimise risk of 
transmission and acquisition of such pathogens. The effectiveness of face masks in a CF population 
has not been studied extensively. 
To address the knowledge gaps highlighted above, this thesis had two key aims:  
i) To determine if CF pathogens other than P. aeruginosa can be aerosolised during coughing, 
 and to investigate their survival in the air over distance and time and; 
ii) To examine the effectiveness of face masks and cough etiquette in reducing the outward 
 dispersal of cough generated aerosols containing P. aeruginosa in people with CF. 
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Methods 
i)  Cough aerosolisation of cystic fibrosis respiratory pathogens (other than P. aeruginosa)  
Thirty-three participants with CF were enrolled, according to a recent history of infection with: 1) 
Gram-negative bacteria (GNB) other than P. aeruginosa; 2) S. aureus and; 3) M. abscessus complex. 
Using two validated systems for aerosol sampling, the viability and survival of cough aerosols were 
measured over distance and time.  
ii)  Effectiveness of face masks and cough etiquette to reduce aerosol concentration of 
 Pseudomonas aeruginosa  
Twenty-five participants with CF and chronic P. aeruginosa infection were enrolled. Six respiratory 
activities of talking and coughing, with and without face masks were undertaken within an aerosol 
sampling device. Aerosols were collected at 2-metres and quantitative analysis performed on bacterial 
colony forming units (CFU) for each intervention. Subjects rated their comfort levels when wearing 
masks during each cough activity.  
Results 
People with CF and respiratory infections including: S. maltophilia, Achromobacter spp., B. cepacia 
spp., and S. aureus can aerosolise these organisms during coughing. All species were detected within 
droplet nuclei at 4-metres from source and up to 45-minutes after generation. A correlation between 
bacterial aerosol concentration and sputum load was demonstrated for GNB (r=0.50, p=0.035) and S. 
aureus (r=0.66, p=0.005) (Chapter 2). 
M. abscessus can be aerosolised during coughing and survive (presumably on inanimate surfaces) for 
up to 24-hours. Viable aerosols were detected when there was greater burden of respiratory infection 
(Chapter 3). 
During uncovered coughing, 19/25 (76%) subjects produced viable P. aeruginosa aerosols at 2-  
metres, with a positive correlation observed between the P. aeruginosa sputum load and the aerosol 
bacterial concentration (r=0.55, p=0.01). The surgical mask (p˂0.001), the N95 mask (p˂0.001) and 
cough etiquette (p˂0.001) were effective at reducing cough aerosols containing P. aeruginosa by 94, 
94 and 53%, respectively when compared to uncovered coughing. The surgical mask was rated more 
comfortable than the N95 mask (p=0.004) (Chapter 4). 
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Conclusions 
This thesis demonstrates that common CF pathogens are aerosolised during coughing and survive for 
extended periods within droplet nuclei, suggesting that airborne transmission is plausible for the 
organisms measured. This finding suggests that stringent infection control practices are required for 
people with CF. 
Face masks significantly reduce the outward dispersal of cough generated P. aeruginosa aerosols, 
whereas cough etiquette is less effective. These data support the recent infection control 
recommendations for people with CF to wear a surgical mask in common areas of healthcare facilities 
to reduce potential transmission of pathogens. 
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Chapter 1:  Review of Literature   
1.1   Cystic fibrosis  
Cystic fibrosis (CF) is the most common, lethal genetic condition in Caucasian populations 
(Elborn 2016). The inherited disease is autosomal recessive and is caused by gene mutations 
that encode for the cystic fibrosis transmembrane conductance regulator (CFTR) protein 
(O'Sullivan and Freedman 2009).  The gene responsible for causing CF was identified on the 
long arm of Chromosome 7 in 1989 (Riordan et al. 1989) and since then over 2000 CFTR 
mutations have been discovered and reported (Cystic Fibrosis Mutation Database website 
http://www.genet.sickkids.on.ca/app).  The clinical relevance of the majority of these variants 
is unknown, with 312 classified as disease causing in 2017 (Clinical and Functional Translation 
of CFTR (CFTR2) website http://www.cftr2.org/), an increase from 127 in 2013 (Sosnay et al. 
2013). The CFTR mutations are grouped into six functional classes, according to the molecular 
consequence of the protein expression (Boyle and De Boeck 2013). Severe phenotypical 
features of CF, including high sweat chloride elevation and pancreatic insufficiency is typically 
observed in people with two Class 1 to 3 mutations, whereas those with one (or two) Class 4 
to 6 mutations may not be detected in newborn screening leading to a diagnosis later in life and 
a tendency to lower rates of pancreatic insufficiency and lower sweat chloride levels (McKone 
et al. 2006). The most common mutant allele, p.F508del (Class 2) results from a deletion in 
phenylalanine at codon 508 and approximately 70% of the global CF population have one copy 
of this mutation (Kerem et al. 1989; Bobadilla et al. 2002; McKone et al. 2006).  In Australia, 
50% of individuals with CF are homozygous for the F508del-CFTR mutation and 92% are 
heterozygous for this mutation (Cystic Fibrosis Australia 2017). 
The CFTR protein functions as a cAMP-dependent chloride channel and its primary role is to 
regulate ion and water movement across the apical membrane of epithelial cells in many organs 
including the lungs, pancreas, sweat glands, gastrointestinal tract and vas deferens (Li et al. 
1988; Davis 2006). Within the airways, functional CFTR contributes to maintaining the ionic 
composition, osmolality and volume of the airway surface liquid (ASL), which is essential for 
effective cilia beating and mucociliary clearance. CFTR gene mutations result in impaired 
chloride transport and excessive sodium absorption leading to disease manifestations of 
repeated pulmonary infection, pancreatic insufficiency, malabsorption and male infertility 
(Davis 2006; Elborn 2016).  
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1.1.1   Epidemiology of cystic fibrosis 
The incidence of CF in Australia is approximately 1 in 3000 live births (Bell et al. 2011) and 
1 in 25 people are carriers of a CF gene mutation (Massie et al. 2005). The survival and health 
outcomes of people diagnosed with CF have increased significantly in the last five decades, 
with the median age of survival now over 40 years in many countries (Elborn 2016; Burgel et 
al. 2017), and has surpassed 50 years of age in Canada (Stephenson et al. 2017). Previously 
considered a disease of children, a life expectancy into the sixth decade is now projected for 
those born with CF (Dodge et al. 2007).  The Australian CF Data Registry reported that for the 
first time in 2014, more than half of the 3300 individuals with CF were adults (Cystic Fibrosis 
Australia 2016).  In Europe, the proportion of adults with CF is predicted to increase to greater 
than 60% of the population within a decade (Burgel et al. 2017). Earlier diagnosis through 
neonatal screening programs, multidisciplinary care in specialist centres and aggressive 
nutritional and antibiotic management are thought to have played key roles in improved 
longevity in individuals with CF (O'Sullivan and Freedman 2009). More recently, 
revolutionary therapeutic development of CFTR modulator therapies that correct the 
underlying protein defect of CFTR dysfunction have resulted in significant clinical 
improvements for individuals with CF possessing certain genotypes (Ramsey et al. 2011; 
Wainwright et al. 2015; Rowe et al. 2017; Taylor-Cousar et al. 2017).  
1.1.2  Cystic fibrosis respiratory disease 
Cystic fibrosis is a multisystem condition, however, progressive respiratory disease as a 
consequence of repeated pulmonary infective exacerbations remains the major cause of 
morbidity and mortality (Gibson et al. 2003; Lipuma 2010). Although the newborn CF lung is 
thought to be anatomically normal, excessive neutrophilic inflammation is present early 
(Ranganathan et al. 2011). CFTR absence or dysfunction results in dehydration of the airway 
surface liquid, a build-up of thick, viscous respiratory secretions and ineffective bronchial 
clearance, predisposing individuals with CF to initial, intermittent respiratory bacterial 
infection by opportunistic pathogens  (Davis 2006; Elborn 2016). Later, chronic bacterial 
infection is established and a persistent inflammatory state is elicited in response to persistent 
endobronchial infection  (Davis 2006).  Bacterial and neutrophil products ultimately contribute 
to progressive lung structure destruction, respiratory failure and premature death (Strausbaugh 
and Davis 2007; Boyle and De Boeck 2013).  
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1.2   Cystic fibrosis respiratory microbiology overview 
Cystic fibrosis is characterised by persistent bronchial infection, and a limited group of 
pathogens is traditionally responsible. Changes in the airway bacterial infections are often 
observed in an age-dependent pattern during the lifetime of a patient with CF (Strausbaugh and 
Davis 2007).  While the common human pathogens Haemophilus influenzae and 
Staphylococcus aureus are frequently the first bacteria to be identified within CF respiratory 
secretions during childhood, Pseudomonas aeruginosa infection increases with age and 
predominates in the adult CF population (Cystic Fibrosis Australia 2017; Cystic Fibrosis 
Foundation 2017). Increasing prevalence of methicillin-resistant S. aureus (MRSA) strains and 
other non-lactose fermenting Gram-negative bacterial species including Burkholderia cepacia 
complex, Achromobacter xylosoxidans and Stenotrophomonas maltophilia are typically 
observed in the older age group with a more advanced respiratory disease state (Lipuma 2010; 
Ciofu et al. 2013). Fungi species including Aspergillus and nontuberculous mycobacterium are 
also associated with CF lung infection (Lipuma 2010). 
1.3  Cystic fibrosis bacterial pathogens 
1.3.1   Pseudomonas aeruginosa  
P. aeruginosa are versatile and ubiquitous Gram-negative bacteria that are widely present in 
aquatic environments, soil, plants and home and health care settings (Festini et al. 2007; Khan 
et al. 2007).  The bacterium ranges in size from 0.5 to 3.0µm and is capable of causing infection 
in humans and animals; P. aeruginosa is considered an opportunistic pathogen and is rarely 
found in immunocompetent persons (Ott et al. 2013).  P. aeruginosa has been shown to persist 
on surfaces for extended periods (Panagea et al. 2005) and contaminate disinfectants (Brooke 
2012). 
1.3.1.1  Clinical significance of P. aeruginosa infection in cystic fibrosis  
P. aeruginosa is the most common and clinically significant of the CF pathogens. Its 
prevalence increases with age and by adulthood, up to 70% of Australian adults with CF are 
chronically infected (Ramsay et al. 2016; Cystic Fibrosis Australia 2017). The US CF Data 
Registry reported a reduction in the rates of infection of P. aeruginosa within their population 
from 58.7% in 2001 to 46.4% in 2016 (Cystic Fibrosis Foundation 2017).  
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Initial infection of the airways with P. aeruginosa is thought to be from environmental 
acquisition (Kidd et al. 2015), is often transient and associated with a non-mucoid phenotype 
that is responsive to anti-microbial therapies and host defences (Lipuma 2010). Early  
P. aeruginosa strains usually possess flagella and are motile within the airways.  Standards of 
CF care guidelines recommend the initiation of eradication therapy at the first respiratory 
isolation of P. aeruginosa to prevent infection becoming established (Doring et al. 2012; 
Mogayzel et al. 2014). Studies have shown a greater than 70% success rate with eradication 
therapies initiated for early P. aeruginosa infection in paediatric populations (Ratjen et al. 
2010; Proesmans et al. 2013). Bacterial adaptive changes are observed with chronic  
P. aeruginosa infection, including a mucoid, non-motile biological profile and biofilm 
formation, which facilitates its ability to withstand the hostile, hypoxic environment of the CF 
lung (Gibson et al. 2003; Lipuma 2010; Ciofu et al. 2013). Despite aggressive anti-
pseudomonal antibiotic regimens, eradication is infrequently achieved for chronic infection 
with mucoid P. aeruginosa in patients with CF (Chernish and Aaron 2003).   
P. aeruginosa airway infection in CF is associated with poorer clinical outcomes, including: 
decreased survival and increased radiological signs (Hudson et al. 1993), slower growth rates 
(Pamukcu et al. 1995) and an accelerated decline in lung function (Kosorok et al. 2001). A 
lower predicted FEV1 of 10% has been reported in a paediatric cohort with P. aeruginosa 
infection, compared to those without infection (Kerem et al. 1990).  
1.3.1.2  Acquisition and transmission of P. aeruginosa infection in cystic fibrosis 
Early studies reported that most individuals with CF harboured genetically diverse or unique 
strains of P. aeruginosa, with the exception of some siblings with CF and individuals with 
close personal contacts (Grothues et al. 1988; Romling et al. 1994). This was suggestive of 
acquisition from an environmental source with the possibility of cross-infection considered 
remote.  However, P. aeruginosa transmission routes and cross-infection was first investigated 
in Danish CF clinics in the 1980’s after the spread of a drug-resistant strain in their paediatric 
cohort was observed (Zimakoff et al. 1983; Hoiby and Pedersen 1989). Soon after in the United 
Kingdom,  genetic molecular testing techniques that allowed bacterial species and strain 
identification provided the first compelling evidence for person-to-person transmission of P. 
aeruginosa. 
5 
 
In the landmark study, Cheng and colleagues used genomic analysis to identify an identical 
ceftazidime-resistant P. aeruginosa strain present in 45% of the Liverpool paediatric clinic 
cohort (Cheng et al. 1996). Subsequently, this strain became known as the Liverpool Epidemic 
Strain and widespread sampling within the hospital setting did not identify an environmental 
source (Cheng et al. 1996; Al-Aloul et al. 2004). The authors concluded that cross-infection 
and single agent antibiotic therapy may have contributed to the outbreak. Stemming from these 
findings, reports soon emerged from other UK CF centres and worldwide including Germany, 
Australia and Canada demonstrating shared CF P. aeruginosa strains within and across their 
clinic populations (Jones et al. 2001; Armstrong et al. 2002; Aaron et al. 2010; Kidd et al. 
2013). A “shared” strain is one that is considered genetically indistinguishable from that found 
in another person when using molecular typing tools (Kidd et al. 2013).  While permanent 
ecological reservoirs have not been identified for many of the reported P. aeruginosa shared 
strains, the prevalent shared genotype known as “Clone C” (initially detected in German 
patients with CF) has been detected in both the natural environment and in clinical samples in 
many countries globally (Romling et al. 1994; Scott and Pitt 2004; Romling et al. 2005). 
Furthermore, infection with shared P. aeruginosa strains has variably had greater adverse 
clinical consequences, including increased antibiotic requirements, higher burden of health 
care and an increase in mortality (Kosorok et al. 2001; Armstrong et al. 2003; Jones et al. 2003; 
Jones et al. 2010; Kidd et al. 2013; Parkins et al. 2018).  However, disease severity may also 
be an important confounder of shared P. aeruginosa acquisition; those with more advanced 
disease are predisposed to increased hospitalisations and outpatient clinic visits and therefore 
have greater potential for cross-infection at healthcare facilities.  The Liverpool Epidemic 
Strain was shown to replace pre-existing strains of P. aeruginosa infection in some patients 
with CF, suggesting increased ability to be transmitted (McCallum et al. 2001). A recent 
observational study in a Canadian CF population found that P. aeruginosa infection with a 
changing genotype was associated with greater decline in FEV1 and body mass index (BMI) 
for an individual (Middleton et al. 2018). 
The earliest report of shared CF P. aeruginosa strain infection in Australia was described in 
2001. Five unrelated paediatric patients (less than 7 years of age) at a Melbourne CF clinic 
enrolled in a prospective cohort study died prematurely and were posthumously identified as 
having respiratory infection with an identical multi-resistant strain of P. aeruginosa (Nixon et 
al. 2001). Subsequent testing of all P. aeruginosa infected patients within this clinic revealed 
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that 55% of the population shared the same strain (Armstrong et al. 2002). Initially known as 
the Melbourne strain and later re-named the Australian Epidemic Strain–I (and now known as 
AUST-01), this strain was later identified in unrelated patients in geographically distant cities 
including Sydney and Brisbane (Armstrong et al. 2003).  
More recently, a large national study conducted molecular sequencing of 2887 P. aeruginosa 
samples from patients attending eighteen CF centres in Australia (Kidd et al. 2013). The study 
revealed that nearly two thirds of people with CF possessed a P. aeruginosa strain that was 
shared by another person (Kidd et al. 2013). The two most common genotypes, AUST-01 and 
AUST-02 were detected in nearly all of the CF centres despite large geographical separations, 
suggesting that that acquisition from a common environmental source was unlikely (Kidd et 
al. 2013).  In fact, extensive ecological studies revealed that CF patient derived respiratory 
secretions were the only reservoir for the dominant shared strain in Queensland, AUST-02 
(Kidd et al. 2012).  
Linkages between Australian CF Centres and individual patient movements as a potential risk 
factor for acquisition of some of the Australian major shared strains of P. aeruginosa was 
recently described (Kidd et al. 2015). A number of studies have also reported the transmission 
of P. aeruginosa during prolonged social interactions of patients with CF outside of the hospital 
environment (Ojeniyi et al. 2000; Brimicombe et al. 2008). Collectively, these epidemiological 
studies demonstrate that unrelated individuals with CF can be infected with genetically 
indistinguishable strains of P. aeruginosa. In the absence of ecological niches being identified 
as common sources, it provides strong evidence for cross-infection. However, the exact routes 
of potential transmission are not clear. Recent studies suggest that airborne transmission of P. 
aeruginosa may be possible; individuals with CF can aerosolise P. aeruginosa during 
coughing, which  remain viable within droplet nuclei for extended durations (Wainwright et 
al. 2009; Knibbs et al. 2014). 
1.3.2   Achromobacter species 
The Achromobacter species contains seven subspecies, of which A. xylosoxidans is most 
commonly identified as causing respiratory infection in people with CF (Spilker et al. 2013). 
A. xylosoxidans is an aerobic, Gram-negative bacillus and an opportunistic pathogen that is 
found widely in the natural environment. It has been isolated in clinical samples and can survive 
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on inanimate objects; thus representing an important cause of human pulmonary and 
nosocomial infection, especially amongst immunosuppressed patients (Duggan et al. 1996). 
1.3.2.1  Clinical significance, acquisition and transmission of A. xylosoxidans in 
cystic fibrosis 
A. xylosoxidans is considered an emerging CF pathogen (Lipuma 2010). Although a low 
prevalence rate of 2.5% is reported in the Australian CF cohort (Cystic Fibrosis Australia 
2017), an increase from 1.9% to 6% was described in the US CF population in the decade up 
to 2005 (Razvi et al. 2009). The contribution of A. xylosoxidans to CF pulmonary infection 
remains uncertain, in part due to the relatively low number of patients infected with this 
organism.  One study has reported that A. xylosoxidans infection does not impact lung function 
(De Baets et al. 2007), whereas a longitudinal study found an increased risk of death and 
transplantation in those with chronic infection (Somayaji et al. 2017). More commonly 
detected within the adult population, it is unclear whether A. xylosoxidans contributes to disease 
progression or its presence in the airway reflects more severe lung disease (Hauser et al. 2011). 
One factor proposed for the increasing recovery of this highly antibiotic resistant organism 
from CF respiratory samples is the selective pressure on bacterial populations relating to the 
aggressive use of anti-pseudomonal therapies (Ridderberg et al. 2012). 
It has been reported that sibling patients (Peltroche-Llacshuanga et al. 1998) and CF 
individuals with prolonged social contact can harbour indistinguishable genetic strains of  
A. xylosoxidans (Krzewinski et al. 2001). Additionally, some single centre studies have 
demonstrated small clusters of genetically related strains, suggesting that cross-infection or 
acquisition from common sources may occur (Kanellopoulou et al. 2004; Lambiase et al. 2011; 
Ridderberg et al. 2011), although these findings have not been supported by environmental 
epidemiological studies.  Recently, Hansen et al. reported two case studies of suspected indirect 
transmission of a closely related species, Achromobacter ruhlandii in patients with CF (Hansen 
et al. 2013). Cross-infection was suspected despite adherence to standard infection control 
precautions preventing droplet or direct contact pathways, and airborne transmission was 
postulated as a possible route (Hansen et al. 2013). 
1.3.3   Stenotrophomonas maltophilia  
S. maltophilia is a rod-shaped, obligate Gram-negative aerobic bacteria that can exist in a range 
of ecological niches including aqueous environments, soils and plants. It is considered an 
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opportunistic human pathogen and has been found in both health-care and non-clinical settings 
(Brooke 2012; Hansen 2012).  Although not considered highly virulent, it can cause a wide 
variety of diseases and significant nosocomial infection, especially in humans who are 
immunocompromised (Brooke 2012). 
1.3.3.1  Clinical Significance, acquisition and transmission of S. maltophilia in 
cystic fibrosis 
Cystic fibrosis centres globally have reported increasing rates of S. maltophilia recovery from 
sputa in the last decade, with prevalence wide-ranging from 8.3%  in Australia (Cystic Fibrosis 
Australia 2017) to 30% within a single European CF Centre (Dalboge et al. 2011).  
S. maltophilia displays multi-resistant patterns to many of the commonly used anti-
pseudomonal antibiotics (Denton et al. 1996) and repeated exposure to such therapies is 
considered one factor underpinning the increased occurrence of this bacterium within CF 
populations (Denton et al. 1996; Amin and Waters 2014).  
The clinical impact of chronic S. maltophilia infection on health outcomes in people with CF 
is not well defined. While chronic S. maltophilia airway colonisation has been associated with 
immunological reaction suggesting infection and a risk factor for pulmonary exacerbation 
(Waters et al. 2011), its role in lung decline remains unclear.  Some studies demonstrated no 
adverse impact on survival in people with CF, nor on rate of lung function decline after 
acquisition of S. maltophilia (Goss et al. 2002; Goss et al. 2004; Dalboge et al. 2011; Hansen 
2012). However, a recent study by Waters et al. reported chronic S. maltophilia infection was 
an independent risk factor for mortality and for lung transplantation (Waters et al. 2013). 
Overall, evidence remains inconclusive as to whether this bacterium is a causative agent in CF 
disease or whether it represents a marker of disease severity (Hansen 2012; Waters et al. 2013).   
As such, there is no current consensus regarding approaches to treatment (including timing and 
antibiotic choice) of S. maltophilia infection (Hansen 2012; Amin and Waters 2014). 
The modes of acquisition and routes of transmission for S. maltophilia remain unclear. S. 
maltophilia are capable of forming biofilms (Pompilio et al. 2011) and adhering to plastics 
(Brooke 2012).  The bacterium has been detected in water supplies and devices supplying water 
e.g. taps and drinking water pipes within health care environments (Denton et al. 2003; Guyot 
et al. 2013). Furthermore, nebulisers used by patients with CF in the home and hospital setting 
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have been found contaminated with S. maltophilia (Hutchinson et al. 1996), suggesting 
inadequate cleaning methods as a possible contributing factor to acquisition. 
While outbreaks of S. maltophilia relating to contact transmission have been documented 
within hospital settings (Lanotte et al. 2003), this has not occurred within the CF population. 
A study from the Copenhagen CF Centre that used pulsed-field gel electrophoresis, found only 
unique strains in the chronically infected cohort, indicating cross-infection was unlikely to have 
occurred (Dalboge et al. 2011). At present, the acquisition of S. maltophilia infection appears 
to occur from independent natural environmental sources.   
1.3.4   Burkholderia cepacia complex (BCC) 
Burkholderia cepacia complex contains over 20  species, some of which were previously 
referred to as genomovars (Saiman et al. 2014; Kenna et al. 2017). Burkholderia cepacia is a 
Gram-negative rod, found in a broad range of environmental niches and is a recognised plant 
pathogen associated with onion rot (Mahenthiralingam et al. 2008). The bacterium is versatile 
and robust and has been found to exist in hospital antiseptics and disinfectants (Oie and Kamiya 
1996) and resist drying, which enhances its ability to survive on surfaces (Drabick et al. 1996); 
properties which may contribute to its role in nosocomial infection.   
1.3.4.1  Clinical significance, acquisition and transmission of Burkholderia cepacia 
complex in cystic fibrosis 
The clinical significance and pathogenic consequence of BCC infection on CF lung disease is 
unknown for most species. However, B. multivorans and B. cenocepacia are the most common 
species isolated from CF respiratory samples (Mahenthiralingam and Vandamme 2005) and , 
along with B. dolosa (Kalish et al. 2006) have been implicated in ‘cepacia syndrome’, a 
condition that has been described in people with CF that can include sepsis, a progressive 
pneumonic process and may be associated with accelerated clinical deterioration and increased 
mortality (Isles et al. 1984; Blackburn et al. 2004). Certain strains of B. cenocepacia have high 
rates of transmissibility (e.g. ET-12 strain and the Czech strain (ST-32)) (Drevinek and 
Mahenthiralingam 2010) and broad spectrum antibiotic resistance (Govan et al. 1993; Lipuma 
2005). Infection with  B. cenocepacia may be a contraindication to lung transplantation in many 
CF centres worldwide, following reports of reduced survival (Alexander et al. 2008) and poor 
post-operative clinical outcomes  in those with pre-existing infection (Hadjiliadis 2007). 
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Burkholderia cepacia complex was responsible for significant outbreaks in the 1990’s 
associated with person-to-person transmission in CF cohorts, both within and between centres. 
Acquisition of BCC epidemic strains was often associated with devastating clinical 
consequences (LiPuma et al. 1990; Govan et al. 1993). These early reports provided evidence 
for cross-infection that was thought to have arisen from direct or indirect contact such as droplet 
transmission. BCC has been found to survive on inanimate surfaces, with an extended survival 
period when suspended in CF sputum (Drabick et al. 1996). Airborne transmission is 
considered possible based on studies that demonstrated positive air sampling of the rooms of 
chronically infected patients during and after airway clearance techniques (Ensor et al. 1996), 
often persisting for up to 45 minutes (Humphreys et al. 1994).  More recently, Wainwright and 
colleagues demonstrated that individuals with CF can aerosolise BCC during coughing, 
providing further evidence for possible airborne transmission (Wainwright et al. 2009). 
A consistent decline in incidence of BCC has been observed worldwide in CF centres over the 
last decade, with prevalence rates currently below 3% in both Australia (Cystic Fibrosis 
Australia 2017) and the USA (Cystic Fibrosis Foundation 2013; Cystic Fibrosis Foundation 
2017). Specifically, the epidemiology has changed from B. cenocepacia as the dominant 
species in CF, to B. multivorans (Zlosnik et al. 2015); this has been attributed to the success  
of infection control policies that include strict cohort segregation, adopted by CF centres 
globally for people infected with BCC in response to outbreaks (Govan et al. 1993; Whiteford 
et al. 1995; Chen et al. 2001; France et al. 2008; Zlosnik et al. 2015). Following the 
introduction of these measures for people with CF and BCC infection, studies have reported 
increased genetic strain diversity amongst new incident cases, suggesting environmental 
acquisition sources rather than person-to-person transmission (Turton et al. 2003; France et al. 
2008; Ramsay et al. 2013).  
1.3.5   Staphylococcus aureus 
S. aureus is a Gram-positive coccal organism. It is a human commensal, often detected 
colonising the nares, which may provide the source of infection for susceptible individuals. 
1.3.5.1  Clinical significance, acquisition and transmission of S. aureus in cystic 
fibrosis 
S. aureus is often the first bacterium isolated from the airways from people with CF, and has a 
peak prevalence during the child and adolescent age group (Lipuma 2010). A multicentre 
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Australian study reported a prevalence of S. aureus of 30% in children with CF aged 5 years 
(Wainwright et al. 2011). In the total Australian CF population, S. aureus was detected in 
33.9% of respiratory cultures in 2015 (Cystic Fibrosis Australia 2017).  The prevalence rates 
of Methicillin-resistant S. aureus are wide ranging in different countries with 2.6% reported in 
Australia (Cystic Fibrosis Australia 2017) to 26% in the USA (Cystic Fibrosis Foundation 
2017). While Australia has reported a gradual decline in the prevalence of MRSA within the 
CF population over the last decade (Cystic Fibrosis Australia 2017), the USA has noted a 
dramatic increase over the same time, which mirrors the increased incidence in community 
associated MRSA observed in the general American population (Hauser et al. 2011).  
Although considered a CF pathogen, opinions differ as to the contribution of S. aureus to 
disease, with some arguing that its presence has minimal clinical impact (Lyczak et al. 2002). 
However, poorer nutritional status and associated pulmonary inflammation has been 
demonstrated in infants with S. aureus infection (Ranganathan et al. 2011). 
The clinical significance of MRSA respiratory infection in CF in the literature has evolved in 
recent years.  An early study found that acquisition of respiratory MRSA did not significantly 
alter lung function (Miall et al. 2001), whereas results from subsequent studies involving larger 
cohorts of people with CF describe a negative impact of MRSA infection, including poorer 
clinical outcomes including increased rate of lung function decline, increased treatment burden 
and reduced survival (Ren et al. 2007; Dasenbrook et al. 2008; Dasenbrook et al. 2010).  In 
contrast, another study found that there was a faster rate of lung function decline in individuals 
prior to acquisition of MRSA, but once detected the rate of lung function decline was not 
impacted (Sawicki et al. 2009). 
Contact spread via contaminated hands or surfaces is considered the predominant route of 
transmission of MRSA nosocomial infection, with the contribution of aerosol dispersal 
undetermined.  It is been suggested that peptidoglycan cell wall characteristics of Gram-
positive organisms may provide protection from aerosol desiccation, enhancing perseverance 
in an airborne state for durations exceeding that of Gram-negative organisms (Beggs 2003). 
Studies have isolated S. aureus, including MRSA, from air samples in CF care related areas 
within hospital facilities (Ferroni et al. 2008; Zuckerman et al. 2009; Zuckerman et al. 2015). 
Staphylococcus epidermidis has been shown to exist as in-vitro generated aerosols  for 
extended periods and have a particle size within the respirable range (Thompson et al. 2011), 
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but to date no studies have investigated the viability of Gram-positive organisms generated 
directly from cough aerosols of patients with CF.  
1.3.6   Non-tuberculosis mycobacteria (NTM) 
Non-tuberculous mycobacteria are ubiquitous environmental organisms and the most common 
source of human acquisition is considered exposure to soil and water. Improvements in 
technologies have seen over 125 NTM species catalogued (Griffith et al. 2007). People with 
established underlying respiratory disease or compromised systemic immunity status are 
particularly susceptible to this opportunistic organism (Griffith et al. 2007). The incidence and 
prevalence of NTM respiratory infection are increasing globally and extreme weather patterns 
and natural disasters associated with climate change has been postulated as a contributing factor 
for this observation (Honda et al. 2015).   
1.3.6.1  Clinical significance, acquisition and transmission of NTM in cystic fibrosis 
Since the first reported case in a CF patient in the 1980’s (Boxerbaum 1980), NTM have 
emerged as a significant pathogen in people CF, with prevalence rates within different 
countries ranging from 6.6% in France (Roux et al. 2009), 11% in Scandinavia (Qvist et al. 
2015) and 13% in USA (Olivier et al. 2003). Consistently, CF clinics globally are reporting 
increasing prevalence rates of NTM in recent years (Renna et al. 2011; Bar-On et al. 2015; 
Cystic Fibrosis Foundation 2017).  The Australian CF Data Registry reported a prevalence rate 
of NTM of 2.8% in 2015 (Cystic Fibrosis Australia 2017). The contribution that growing 
attention to these organisms through increased surveillance practices and advancements in 
detection and laboratory processing has played in the rising prevalence rates is unclear. An 
Israeli CF Centre reported an increased in prevalence of NTM infection from 0% to 9% in their 
cohort, despite consistent laboratory techniques over the decade in which this change was 
observed (Bar-On et al. 2015).  
While NTM can cause a wide variety of clinical manifestations including soft tissue infection, 
disease tends to be restricted primarily to the lung within the pre-transplanted CF population 
(Olivier et al. 2003). Formal diagnosis of NTM pulmonary disease requires assessment against 
pre-determined clinical, radiological and microbiological criteria (Griffith et al. 2007). The 
diagnosis in a person with CF is challenging owing to pre-existing lung structural damage and 
daily respiratory symptoms (Griffith et al. 2007). As a result, a positive NTM culture in 
individuals with CF may be an incidental finding during regular sputum surveillance. 
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Risk factors relating to isolation of NTM in people with CF have been identified as increased 
age (Olivier et al. 2003), co-infection with S. maltophilia and Aspergillus species (Esther et al. 
2010) and more severe CF genotype (Roux et al. 2009; Bar-On et al. 2015).  Controversy exists 
over the association of NTM infection with macrolide therapy; one study reported the use of 
Azithromycin may predispose individuals with CF to NTM infection (Renna et al. 2011), 
whereas recent studies demonstrate a protective effect from this macrolide (Binder et al. 2013; 
Coolen et al. 2015; Sherrard et al. 2017).  
The Mycobacterium abscessus complex (MABSC) and Mycobacterium avium complex 
(MAC), which includes M. avium and M. intracellulare are responsible for the majority of 
NTM infection in the CF population (Olivier et al. 2003). The causative dominant species of 
CF infection differs globally; the slow-growing MAC species has higher prevalence rates in 
the USA, whereas the rapid-growing MABSC is the dominant species of CF populations in 
Western Europe (Roux et al. 2009), Scandinavia (Qvist et al. 2015), Israel (Levy et al. 2008) 
and some geographical areas of Australia (Sherrard et al. 2017). 
1.3.6.2  Mycobacterium abscessus complex 
The Mycobacterium abscessus complex of bacteria comprises three subspecies: M. abscessus 
subsp. massiliense, M. abscessus subsp. bolletii and M. abscessus subsp. abscessus (Floto and 
Haworth 2015). M. abscessus is a multidrug resistant organism that is difficult to treat and 
eradicate, and respiratory infection in patients with CF has been associated with an accelerated 
loss of lung function and decline in clinical status (Esther et al. 2010; Qvist et al. 2016). Poor 
clinical outcomes, including disseminated M. abscessus infection post lung transplantation 
(Sanguinetti et al. 2001; Taylor and Palmer 2006) has resulted in some centres excluding 
individuals with active disease from transplant listing.  However, other studies describe 
acceptable recovery and outcomes following lung transplantation in small numbers of patients 
with CF and M. abscessus infection and recommended that while there may be increased post-
operative complications, active infection should not be an absolute contraindication (Gilljam 
et al. 2010; Qvist et al. 2013). 
Unlike Mycobacterium tuberculosis which is highly transmissible, earlier studies considered 
person-to-person transmission of M. abscessus (and for that matter, all NTM) unlikely and 
nosocomial acquisition did not occur (Olivier et al. 2003; Sermet-Gaudelus et al. 2003). 
However, molecular technologies confirmed that recent outbreaks of M. abscessus at CF 
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Centres in the UK and USA could represent cross-infection, despite adherence to segregation 
policies that minimise contact and droplet transmission (Aitken et al. 2012; Bryant et al. 2013).  
An individual at the Seattle CF clinic with high mycobacterial burden (AFB smear 4+) was 
identified as an index case in a small outbreak of M. abscessus subsp. massiliense and thought 
to be responsible for the acquired infection in four other clinic attendees (Aitken et al. 2012). 
Despite overlapping clinic days, direct contact did not occur between the index case and the 
four patients subsequently infected. Indirect contact via fomites or airborne dissemination were 
considered possible transmission pathways (Aitken et al. 2012). Two of the infected cases 
experienced sudden deterioration in clinical status and death within months of the  
M. abscessus subsp. massiliense acquisition. The CF Centre immediately enacted strict 
cleaning regimens and airborne isolation rooms for patients infected with M. abscessus and 
seemingly containing the outbreak (Aitken et al. 2012).   
Using whole-genome sequencing and antibiotic resistance patterns, the Papworth CF Centre, 
UK identified near-identical isolates of M. abscessus subsp. massiliense during an outbreak in 
a group of eleven patients (Bryant et al. 2013). Extensive water and environmental sampling 
at the time of the outbreak did not identify reservoirs containing the organism. Direct patient 
contact between those infected was excluded, with speculation that cross-infection may have 
occurred by contaminated fomites or by the airborne route (Bryant et al. 2013).  
Whilst airborne dispersal of M. tuberculosis is a known transmission pathway and people with 
active infection can generate culturable aerosols (Fennelly et al. 2012), studies have not been 
undertaken to determine if people with CF and M. abscessus infection generate viable aerosols 
during coughing and pose a cross-infection risk. 
1.3.7   Cystic fibrosis lung microbiome 
Microbiome studies have demonstrated a vast array of bacteria not previously detected on 
culture based methods, revealing that the CF airway comprises complex microbial colonies 
outside the well-researched traditional pathogens. Studies have demonstrated that younger 
people with CF and those with less antibiotic exposure and with preserved lung function tend 
to have greater bacterial airway diversity; the most prevalent species being oropharyngeal flora, 
anaerobes and Staphylococcus and Haemophilus (Cox et al. 2010; Zhao et al. 2012). 
Furthermore, bacterial diversity decreases with increasing age and advancing lung disease in a 
patient with CF, whilst density of the bacterial species increases (Cox et al. 2010).  Reduced 
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bacterial diversity has been correlated with lung function decline and coincides with the 
appearance of dominant genera including Pseudomonas and Burkholderia (Cox et al. 2010). 
There is little deviation of the microbiome of an individual with clinical interventions including 
antimicrobial administration during pulmonary exacerbations (Cox et al. 2010; Zhao et al. 
2012). 
Overall, greater bacterial species airway diversity appears to be associated with better 
pulmonary health in people with CF (Lynch and Bruce 2013). 
1.4   Acquisition of cystic fibrosis pathogens 
The source and mechanism of acquisition of airway bacterial pathogens in patients with CF is 
not well understood, and was previously considered to be principally from the natural 
environment. This was supported by studies that demonstrated the majority of people with CF 
harboured genetically diverse or unique strains of organisms (Grothues et al. 1988; Romling et 
al. 1994). However, significant advances in genetic molecular typing techniques and extensive 
epidemiological studies conducted in CF centres worldwide have provided evidence that 
unrelated patients with CF can harbour genetically indistinguishable, also known as “shared” 
bacterial strains in their respiratory samples (Cheng et al. 1996; Jones et al. 2001; Armstrong 
et al. 2003; Aaron et al. 2010; Kidd et al. 2013).  This has been demonstrated convincingly for 
the dominant airway pathogen found in global CF populations, P. aeruginosa and BCC 
(LiPuma et al. 1990; Govan et al. 1993). Despite extensive health facility and ecological 
sampling, common environmental reservoirs for many of the shared strains have not been 
identified (Cheng et al. 1996; Kidd et al. 2013), which suggests that cross-infection may be a 
mechanism by which P. aeruginosa, and potentially other CF pathogens, is acquired.  
1.5   Routes of respiratory bacterial transmission  
Respiratory bacterial and viral transmission between humans is known to occur by three key 
routes:  
 1) contact transmission, where a susceptible host comes into direct contact with 
respiratory secretions from an infectious source, or by indirect contact with a contaminated 
inanimate surface (e.g. fomite).  In addition to Standard Precautions of hand hygiene, gown 
and gloves are recommended for healthcare professionals when caring for patients under 
Contact Precautions (Saiman et al. 2014); 
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 2) droplet transmission, where particles containing infectious material >5µm generated 
from respiratory activities, such as talking, sneezing and coughing can travel up to one metre 
and impact on the mucosal surfaces of a susceptible recipient (World Health Organization 
2014). Surgical face masks are recommended for healthcare professionals when caring for 
patients under Droplet Precautions and for people with CF when in communal areas of 
healthcare facilities (Saiman et al. 2014);  
  3) airborne transmission, where microbe laden droplets dehydrate to become droplet 
nuclei ≤5µm in size and, capable of remaining suspended in the atmosphere for extended 
durations, which can be  inhaled by a recipient, who may not be in close proximity to the source 
(Beggs 2003; Siegel et al. 2007; World Health Organization 2014). The airborne route is 
known to be a transmission pathway in rubeola virus (measles), varicella zoster virus, 
Bordetella pertussis and M. tuberculosis infection (Riley et al. 1962; Remington et al. 1985; 
Warfel et al. 2012; MacIntyre and Chughtai 2015).  N95 or respirator masks are recommended 
for healthcare professionals when caring for patients under Airborne precautions.   
1.6   Human bioaerosols 
An aerosol is a solid or liquid suspended in the air or gaseous environment. Human activities 
of breathing, talking and coughing generate aerosols over more than three orders of magnitude 
in size from 10nm to 500µm (Gralton et al. 2011; Johnson 2011), and these are capable of 
infecting a susceptible host if they contain viable microbes. While the particle size distribution 
of cough aerosols from individuals with CF has not previously been reported,  Zayas et al., 
demonstrated that the 97% of droplet particles produced in a healthy volunteer cough are <1µm 
(Zayas et al. 2012). Factors known to reduce survival of aerosolised bacteria include increased 
humidity, reduced temperature and smaller particle size (Thompson et al. 2011).  
1.6.1   Methods to detect bioaerosols 
The most commonly used air sampling methods to detect viable bioaerosols include the 
principles of: impaction, impingement and filtration (Pillai and Ricke 2002).  
1.6.1.1  Andersen Cascade Impactor 
The six-stage Andersen Cascade Impactor (ACI) (6 STG Viable Particle Sampler, Andersen 
Instruments Inc., Atlanta, GA)  (Andersen 1958) is widely used and considered the benchmark 
17 
 
for bioaerosol sampling (Jensen et al. 1992). A vacuum pump extracts air samples at a fixed 
rate of 28.3 L/min, and directs this sequentially through six stages of the impactor stacked with 
selected media agar plates for the target organism (Schappi et al. 1997). Each stage has 400 
orifices of decreasing diameter through which the airstream passes. Particles are collected 
progressively, according to size by inertial impaction, with the largest concentrated at the top 
(stage 1) and the smallest particles in the lower stages. The ACI provides particle size 
discrimination ranging between aerodynamic diameters of 0.65 to >7µm (Pillai and Ricke 
2002). This is important in the identification of microbial laden droplet nuclei that may 
potentially infect the human respiratory system through inhalation, with particles in the 
respirable fraction of ≤4.7µm (stages 3 – 6) considered capable of small bronchi and alveolar 
deposition.  
The ACI has been used to collect pathogens directly from patient derived cough aerosols 
(Fennelly et al. 2004; Wainwright et al. 2009; Driessche et al. 2013; Knibbs et al. 2014; 
Driessche et al. 2015) and within their immediate surroundings within health care facilities, 
including inpatient and outpatient settings (Zuckerman et al. 2009; Zuckerman et al. 2015). 
1.7  Air contamination with cystic fibrosis pathogens 
Evidence of airborne transmission as a possible route for P. aeruginosa was reported after the 
detection of positive air samples in the immediate environment of hospitalised patients with 
CF, with the highest concentrations after aerosol producing techniques including airway 
clearance and spirometry (Jones et al. 2003; Panagea et al. 2005; Ferroni et al. 2008). Air 
contamination with BCC and S. aureus has also been isolated from within inpatient and 
outpatient CF settings within healthcare facilities (Humphreys et al. 1994; Jones et al. 2003; 
Panagea et al. 2005; Zuckerman et al. 2009).  Clifton et al. demonstrated with in-vitro studies 
that various strains of P. aeruginosa could be aerosolised when sputa was nebulised (Clifton 
et al. 2008). Mucoid strains of P. aeruginosa exhibited a survival advantage from desiccation 
over non-mucoid types and it was suggested that the exopolysaccharide alginate provided a 
protective covering, while environmental factors of increased temperature and decreased 
humidity had a negative effect on survival (Clifton et al. 2008).  
1.7.1   Cough aerosolisation of cystic fibrosis pathogens 
Recent Australian in-vivo studies demonstrated that during coughing, individuals with CF and 
chronic respiratory infection generate viable aerosols containing droplet nuclei (Wainwright et 
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al. 2009; Knibbs et al. 2014).  Using a cough aerosol sampling system (CASS), Wainwright 
and colleagues found that the majority of infectious aerosolised particles were in the ≤3.3µm 
airborne size range and therefore capable of being inhaled and depositing within the small 
airways (Wainwright et al. 2009). These aerosols contained P. aeruginosa and a small number 
of other Gram-negative pathogens including BCC, S. maltophilia and A. xylosoxidans.  A 
subsequent study by Knibbs et al. revealed that unique and shared strains of P. aeruginosa 
generated from cough aerosols of chronically infected patients with CF could travel up to a 
distance of 4-metres and survive for up to 45-minutes (Knibbs et al. 2014).  In both of these 
studies, the paired P. aeruginosa aerosol and sputum samples collected from individual 
participants on the testing day were genetically indistinguishable by enterobacterial repetitive 
intergenic consensus (ERIC)-PCR analysis (Wainwright et al. 2009; Knibbs et al. 2014). A 
positive correlation between sputum P. aeruginosa load and aerosol concentrations was also 
observed (Wainwright et al. 2009; Knibbs et al. 2014), suggesting that individuals with greater 
sputum bacterial burden may pose a greater risk of airborne dissemination and potential cross-
infection. The study by Wainwright et al. also demonstrated a correlation between FEV1 (L) 
and aerosol concentration of P. aeruginosa, although this association was not observed in the 
more recent study by Knibbs et al. (Wainwright et al. 2009; Knibbs et al. 2014) 
The airborne route has been speculated as having a contributory role in outbreaks of shared 
strains of P. aeruginosa in CF Centres (Jones et al. 2003; Panagea et al. 2005; Wainwright et 
al. 2009), although the specific processes involved are poorly defined. Single CF centres 
recently reported genetically identical strains of M. abscessus and Achromobacter spp. strains 
in sputum samples recently reported with adherence to segregation policies and cross-infection 
by airborne dispersal was postulated as a potential mechanism (Bryant et al. 2013; Hansen et 
al. 2013). Based on these findings, the cough aerosol production and survivability of CF 
pathogens as droplet nuclei demands further investigation, especially as many of the 
“emerging” CF pathogens such as S. maltophilia, Achromobacter spp. and NTM species are 
increasing in prevalence in CF populations, have multi-drug resistance profiles and may pose 
a cross-infection risk to individuals with CF.  
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1.8   Methods to limit aerosol dissemination and transmission 
1.8.1   Cystic Fibrosis Infection Control Guidelines 
Person-to-person transmission of common CF pathogens including P. aeruginosa and BCC has 
occurred within social circles (Govan et al. 1993; Ojeniyi et al. 2000; Brimicombe et al. 2008), 
family households (Grothues et al. 1988) and health care settings (Cheng et al. 1996; 
McCallum et al. 2001).  This prompted a paradigm shift in CF infection control policies over 
the last two decades (Jones et al. 2001; Saiman and Siegel 2004). The initial strategies 
implemented to mitigate person-to-person transmission included cohort segregation based on 
microbiological status and the disbanding of CF communal events and social camps that 
encouraged close interactions of peers with CF (Saiman et al. 2003). These approaches, in 
combination with aggressive eradication protocols for early isolation of P. aeruginosa have 
been credited with the reduced number of individuals transitioning to adult centres with chronic 
P. aeruginosa infection (Saiman et al. 2014; Ramsay et al. 2016). Recent comparative data 
from CF patient data registries has shown a reduction in overall prevalence of P. aeruginosa 
in CF Centres in the US, Canada and Australia (Aaron et al. 2010; Cystic Fibrosis Australia 
2016; Cystic Fibrosis Canada 2016; Cystic Fibrosis Australia 2017; Cystic Fibrosis Foundation 
2017). However, despite the implementation of these strategies to limit close proximity 
transmission (Saiman et al. 2003), cross-infection remains an ongoing problem in CF Centres 
(Lee and Wang de 2011; Aitken et al. 2012; Bryant et al. 2013; Hansen et al. 2013; Kidd et al. 
2013; Kidd et al. 2015). 
Aerosolisation of CF pathogens via droplet nuclei was previously not considered possible, with 
the 2003 Cystic Fibrosis Foundation (CFF) infection control guidelines stating, “it is unlikely 
that P. aeruginosa in the sputum of a CF patient could remain suspended in the air for long 
enough to be transmitted to other patients with CF sharing the same air supply” (Saiman and 
Siegel 2004).  However, findings from contemporary studies have suggested the possibility of 
airborne transmission of CF pathogens in cross-infection (Wainwright et al. 2009; Clifton et 
al. 2010; Bryant et al. 2013; Knibbs et al. 2014; Fletcher et al. 2016). These new data 
demonstrating viability of CF organisms within droplet nuclei had implications for CF 
infection control guidelines, which previously recommended a safe distance of 1 metre between 
individuals with CF (Saiman et al. 2003). While cross-infection occurring via the airborne route 
has not been confirmed, these findings prompted updates to the infection control guidelines in 
2014 to limit potential aerosol dispersal and transmission including: increasing the separation 
20 
 
distance between people with CF to 2-metres, and the recommendation that individuals with 
CF wear surgical face masks in communal areas of health care facilities (Saiman et al. 2014).  
1.8.2   Face masks 
Face masks are employed widely amongst health care workers as a mode of personal protective 
equipment.  Most of the scientific literature describing face mask effectiveness relates to the 
personal protection from inward transmission of infectious particles (Centres for Disease 
Control and Prevention 2015). Commonly used within healthcare facilities are the surgical face 
mask and the N95 mask, with selection according to whether the transmission risk is classified 
as droplet or airborne respectively.  
1.8.2.1  Surgical face mask 
Historically, the surgical mask was intended to prevent the wearer from contaminating the 
immediate sterile environment of operating theatres with their respirable secretions (Gralton 
and McLaws 2010), but they are now used widely as a means of personal protective equipment 
for the wearer against droplet particles and splash events.  When fitted the mask does not 
provide a complete seal, and therefore it is not advised to be used for prevention of inhaled 
airborne pathogens (Centres for Disease Control and Prevention 2015). 
1.8.2.2  N95 face mask  
The N95 mask derives its name from its certified effectiveness in filtering a minimum of 95% 
of non-oil particles approximately 0.3µm in size (Gralton and McLaws 2010). The N95 
consists of 4-5 layers of filtering material and is designed to provide a complete facial seal so 
as to minimise the wearer’s exposure to inhaled airborne contaminants (Johnson et al. 2009). 
N95 masks should therefore be fit tested so as to provide the wearer with maximum filtration 
effectiveness from inward penetration of aerosolised pathogens (Centres for Disease Control 
and Prevention 2015).  
While current guidance recommends the change of masks when visibly soiled or when 
increased resistance to breathing is noted (Centres for Disease Control and Prevention 2015) 
there is no scientific data supporting the optimal duration for wearing an N95 mask, or if 
effectiveness changes with increased wear time. 
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1.8.3   Cough etiquette manoeuvres 
The recommendation of “covering your mouth” whilst coughing is a widely accepted practice 
of health facility guidelines and the cornerstone of community campaigns to minimise the 
spread of infectious particles, especially during viral seasons (Centres for Disease Control and 
Prevention 2015).   
1.8.4   In-vivo effectiveness of face masks and cough etiquette manoeuvres 
A small number of studies have investigated the effectiveness of face masks and cough 
etiquette in non-CF populations and demonstrated an overall reduction in aerosol dispersal, 
however, the effect on smaller airborne sized particles (i.e., droplet nuclei) is unclear, with 
differing arguments presented in the literature (Riley 1974; Tang et al. 2009; Zayas et al. 2013). 
It was postulated that an obstruction in close proximity to the face, such as a hand or surgical 
face mask should be effective, as infectious droplets are impacted onto the surface and unable 
to evaporate into smaller dimension droplet nuclei (Riley 1974). More recently, investigators 
using photographic techniques have demonstrated that the incomplete seal of a surgical mask 
allowed the pressurised airflow created from coughing to be leaked around the edges of the 
mask (Tang et al. 2009). This finding was confirmed and extended by Zayas et al., who used 
a laser diffraction system that measured particle size and concentration and revealed that 
surgical mask usage and hand covering the mouth in healthy volunteers did not prevent aerosol 
production. Instead this study found that expelled particles, mainly in the <1µm range, were 
deflected around the obstruction (Zayas et al. 2013).  Therefore, these findings raise the 
possibility that microbe-laden droplet nuclei might be produced from infectious persons, which 
persist in the redirected airstream. Whether this occurs in patients with CF and chronic 
pulmonary bacterial infection is unclear and requires further study. 
A number of studies have investigated the in-vivo effectiveness of face masks worn by patients 
with respiratory infections on reducing outward airborne particle dispersion, with most 
pertaining to cases of confirmed influenza. A study by Johnson et al. compared the use of 
surgical masks and N95 respirators by patients infected with influenza and found both equally 
effective in limiting short term aerosol emissions, as assessed by cough deposition directly onto 
influenza sampling petri dishes (Johnson et al. 2009). Similarly, Milton et al., used a slit 
impactor to sample aerosols that were coughed into a cone and reported a significant reduction 
of 3.8 fold in viral shedding in influenza infected patients coughing with a surgical mask, 
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compared to unmasked control sessions (Milton et al. 2013). The investigators also noted a 
greater decrease in the number of larger droplets (>5µm) than that observed in the smaller 
droplet nuclei size range with the mask in situ (Milton et al. 2013).   
In a different patient cohort with multidrug resistant tuberculosis, a 56% reduction in infectious 
aerosol was reported when infected patients wore surgical masks, as measured by TB skin 
conversion rates in guinea pigs receiving air supply directly from a TB ward (Dharmadhikari 
et al. 2012). While collectively demonstrating that a surgical mask worn by infectious patients 
may contain the cough effluent and offer some protection to aerosol dispersal, such findings 
should not be extrapolated to a CF population, or P. aeruginosa as the pathogen of interest. 
1.8.5   Effectiveness of face masks in the CF population  
The effectiveness of surgical masks worn by patients with CF has been reported in two recent 
publications; both studies followed the CF Foundation infection control updates.  
In a multi-site study, Zuckerman and colleagues, found no significant difference in rates of air 
contamination of outpatient exam rooms between mask wearing and unmasked patients with 
CF (Zuckerman et al. 2015).  However, the low positive air samples overall (0.7% in the 
unmasked control group) was considerably less than their earlier 2009 study findings of 8% air 
contamination rate in an outpatient setting (Zuckerman et al. 2009), and this may have limited 
the detection of any potential benefit from mask usage. The disparate findings of contamination 
rates in different years may be partly explained by the aerosol collection methods of the two 
studies, in particular the site of placement of the air sampler. In the earlier study, aerosol 
sampling was undertaken with an ACI placed at 1 metre from the patient, compared to 2 metres 
in the 2015 study. This may have led to an overestimation of viable aerosols rather than 
airborne particles exclusively, with droplet particles tending to have a gravitational settling 
radius of 1 metre (Gralton et al. 2011).  
The findings in the study by Driessche et al. demonstrated under controlled laboratory 
conditions that surgical masks provided an 86% reduction in airborne sized P. aeruginosa load 
during coughing in CF patients with chronic pulmonary infection (Driessche et al. 2015). 
Driessche et al. employed voluntary cough manoeuvres, which is known to result in greater 
range of expelled  particle size than talking or breathing, thereby possibly allowing an improved 
detection and comparison rate of viable aerosol (Gralton et al. 2011). Furthermore, the 
laboratory equipment model of 950-litre cough cylinders, which the patients coughed into, was 
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better designed to quantify exhaled emissions than that expelled into a large outpatient exam 
room (Driessche et al. 2015). The findings from these two studies support the need for further 
in-vivo mask studies in patients with CF and highlights the importance of using a system that 
allows assessment of the entire cough aerosol sample, including the relative proportion of 
culturable bacteria and the size distribution of the aerosols.   
1.8.6   Tolerability and physiological constraints of face masks  
Adherence with correct mask wearing technique is known to be a limiting factor in real world 
scenarios, even in high-risk situations (MacIntyre et al. 2009) and amongst health trained 
professionals (Radonovich et al. 2009).  In people with CF, reduced lung function, chronicity 
of sputum production and repetitive cough are factors that have potential to impact mask 
effectiveness and adherence, compared with the general population. Zuckerman et al. reported 
a high rate of mask interference (removal and touching) in their study of people with CF 
attending outpatient clinic (Zuckerman et al. 2015). Most face mask research has focussed on 
adult subjects, but the application of masks for paediatric patients may present additional 
challenges including correct application and adherence compliance with longer duration wear.  
Therefore, the tolerability and physiological constraints of mask wearing in a CF population 
requires exploration.  
In healthy persons, the use of N95 masks has been associated with adverse findings that may 
impact adherence, including: facial discomfort and somatic changes (Radonovich et al. 2009), 
headaches (Lim et al. 2006), increased respiratory resistance (Lee and Wang de 2011) and 
raised carbon dioxide levels (Roberge et al. 2010). As well, increased respiratory distress has 
been reported with mask wearing in people with pulmonary conditions (Johnson et al. 2009).  
While the use of an expiratory valve within the mask may reduce exhalation resistance and 
work of breathing (Roberge et al. 2010), this is unsuitable for infectious persons where the 
purpose of the mask is to limit aerosol expulsion into the environment.  
Considering that the surgical and N95 masks have differing filtering capabilities and associated 
costs and many of the reported compliance issues may be exacerbated in a population with 
pulmonary disease, a trial to quantify the effectiveness and tolerability of both within a CF 
population is required, to ascertain a risk/benefit profile and so as to better inform current CF 
infection control guidelines.  
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1.9   Research Aims and Objectives 
1.9.1  Background and Scope 
Progressive lung disease as a consequence of repeated pulmonary bacterial infections is the 
primary cause of morbidity and mortality in CF.  Understanding the acquisition sources and 
transmission mechanisms of common CF pathogens is integral to prevention. Given that many 
of the common CF pathogens are ubiquitous in the environment, this is the considered the 
major source of acquisition. However, epidemiological studies demonstrating genetically 
indistinguishable bacterial strains in unrelated people with CF have provided compelling 
evidence of cross-infection, although the exact mechanisms are not well understood.  Despite 
the implementation of infection control guidelines that minimise contact and droplet 
transmission, reports of cross-infection of CF pathogens has continued. The airborne route has 
been speculated as a transmission pathway but has not been extensively studied. To address 
this gap in the literature, in-vivo production of viable cough aerosols and survival of CF 
pathogens in the airborne state over distance and time was investigated. The results of this 
study may assist in refinement of existing CF infection control practices to further minimise 
the risk of person-to-person transmission. 
Hospital facilitates provide the greatest risk of cross-infection to CF populations because of the 
potential for interaction in communal areas, indirect contact of contaminated surfaces and 
shared air supply during outpatient clinics and inpatient admissions. Strategies to minimise 
potential transmission pathways are required to protect individuals with CF.  Recent updates 
to the infection control guidelines in some countries have recommended the use of surgical 
face masks by people with CF in common areas of health care facilities, although efficacy and 
tolerability data of such a strategy is limited. To add to the knowledge regarding mitigation 
strategies targeted towards reducing aerosol dispersal, cough etiquette and commonly available 
face masks within a hospital setting were studied. Furthermore, the experiments explored the 
differences in aerosol producing capabilities of talking and coughing in people with CF and 
investigated if clinical characteristics predicted the amount of aerosol concentration generated 
and therefore potential transmission risk.  The results of this study are likely to increase our 
understanding of strategies to reduce aerosol dispersal, ensuring more effective infection 
control practices. 
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1.9.2  Broad Research Aims 
The studies undertaken in this thesis were based on two broad aims:  
i)   Improve the understanding of the potential for airborne transport of common  
  CF pathogens. 
ii)   Investigate the effectiveness of strategies to mitigate outward dispersal of          
 aerosolised P. aeruginosa. 
1.9.3  Specific Research Aims 
The specific aims of the research described in this thesis were to: 
i)     Investigate which of the common CF pathogens including Gram-negative bacteria              
 (other than P. aeruginosa), S. aureus and non-tuberculous mycobacteria could be   
 aerosolised during coughing. 
 
ii) Determine the size distribution of particles containing viable CF pathogens. 
 
iii) Assess the survival of aerosolised CF pathogens over distance and time. 
 
iv) Evaluate the effectiveness of face masks and cough etiquette on reducing aerosol 
 dispersal of aerosolised P. aeruginosa during coughing. 
 
v) Compare the viable aerosol producing capabilities of talking and coughing. 
 
vi) Determine which clinical characteristics, if any, are associated with viable  aerosol 
 concentration generated during coughing. 
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Chapter 2: Cough aerosolisation of common cystic fibrosis pathogens (other than 
Pseudomonas aeruginosa)  
2.1  Abstract 
Rationale: The airborne route is a potential pathway in the person-to-person transmission of 
bacterial strains amongst cystic fibrosis (CF) populations. Cough-generated P. aeruginosa can 
remain viable within droplet nuclei for up 45-minutes and travel up to 4-metres. The 
aerosolisation and survival of other CF pathogens has not been extensively studied.  
Objective: In this cross-sectional study we investigated the physical properties and viability of 
common non-Pseudomonas aeruginosa CF pathogens generated during coughing from 
individuals with CF and current respiratory infection. 
Methods:  Participants with CF were enrolled according to recent respiratory infections:             
(1) non-P. aeruginosa Gram-negative bacteria (GNB) and; (2) Staphylococcus aureus. 
Participants performed a series of voluntary cough manoeuvres into two validated aerosol-
sampling devices that measured viable aerosols at 2 and 4-metres and 5, 15 and 45-minutes 
after coughing.  A 6-stage Anderson Cascade Impactor collected and sized the aerosols, and 
total colony forming units (CFU) were measured. Quantitative sputum and cough aerosol 
cultures were performed and molecular typing undertaken. 
Measurements and Main Results: S. aureus, Stenotrophomonas maltophilia, Achromobacter 
species and Burkholderia cepacia complex were aerosolised during coughing and remained 
viable within droplet nuclei for up to 45-minutes and travelled up to 4-metres. In most cases, 
bacteria detected within the aerosol strain was genetically indistinguishable to that of the 
sputum sample.  
Conclusions:  Common CF pathogens including GNB and S. aureus are aerosolised during 
coughing and have extended survival within droplet nuclei over distance and time.  These 
results suggest airborne person-to-person transmission is plausible for the CF pathogens we 
measured and reinforces the need for universal and stringent infection control practices. 
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2.2  Introduction  
Recurrent pulmonary infection characterises cystic fibrosis (CF). Whilst Pseudomonas 
aeruginosa is generally the most prevalent and clinically significant respiratory pathogen, 
Staphylococcus aureus, Stenotrophomonas maltophilia, Achromobacter and Burkholderia 
species are common (Cystic Fibrosis Australia 2017; Cystic Fibrosis Foundation 2017). 
Epidemiological studies have demonstrated genetically indistinguishable strains of P. 
aeruginosa (Scott and Pitt 2004; Kidd et al. 2015), Burkholderia cepacia complex species 
(Govan et al. 1993) and Mycobacterium abscessus (Bryant et al. 2016), both within and 
between CF centre populations. Environmental reservoirs are infrequently identified for shared 
bacterial strains, suggesting that cross-infection may be a source of acquisition, although the 
precise routes involved remain unclear (Cheng et al. 1996; Kidd et al. 2012; Bryant et al. 2013). 
Some transmissible strains of CF pathogens have been associated with worse clinical outcomes 
and increased health related treatments (Govan et al. 1993; Jones et al. 2010; Kidd et al. 2013), 
further emphasising the importance of understanding transmission pathways.  Despite the 
implementation of infection control policies in many CF centres to limit nosocomial acquisition 
and spread, cross-infection has continued in some instances. The airborne route is a possible 
mode of person-to-person transmission of P. aeruginosa and M. abscessus, which can be 
aerosolised during coughing by people with CF and remain viable within droplet nuclei 
(≤4.7µm in size) for extended durations (Knibbs et al. 2014; Bryant et al. 2016). The extent of 
airborne dissemination of other common CF pathogens has not been studied extensively.     
We studied aerosolisation and survival of common non-P. aeruginosa CF pathogens over 
distance and duration during voluntary coughing, and compared the results with the survival 
of P. aeruginosa. It was hypothesised that individuals with CF produce similar levels of droplet 
nuclei containing Gram-negative bacteria (GNB) and S. aureus during coughing, which can 
travel up to 4-metres (m) and remain viable for up to at 45-minutes (min). 
2.3  Methods 
2.3.1   Study population 
Between May 2015 and July 2016, thirty participants aged ≥ 14 years (adult n=26; adolescent 
n=4) with a confirmed diagnosis of CF were enrolled from CF Centres at The Prince Charles 
Hospital and the Lady Cilento Childrens’ Hospital, Brisbane, Australia. Exclusion criteria 
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included recent haemoptysis (>50mL), recent pneumothorax, pregnancy and history of cough 
syncope.  
Participants were assigned to either GNB or S. aureus groups based on positive sputum 
microbiological results in the prior two years. Clinical demographics and measurements of age, 
gender, weight, and height were recorded. Spirometry was performed on the testing day (Miller 
et al. 2005) and the Global Lung Index predicted scale applied (Stanojevic et al. 2008). An 
expectorated sputum sample was collected and processed by bacterial culture. 
2.3.2  Cough manoeuvres and aerosol sampling 
The experimental equipment was comprised of two validated, independent systems to study the 
distance travelled and survival duration of bacteria contained in aerosols generated during 
coughing (Knibbs et al. 2014).  Participants undertook five cough manoeuvres on the single testing 
day; two within the Distance Rig, and three into the Duration Rig. The Distance Rig comprised 
a closed-system, 4.5-metre perspex tunnel with HEPA-filtered airflow (Knibbs et al. 2014; 
Johnson et al. 2016). Participants were seated and elevated into the rig to their shoulder level. 
They undertook 2-min of tidal breathing and were then requested to cough at a comfortable 
strength and frequency for 5-min. Two tests were undertaken in the Distance Rig with the 
collection point at 2-metres and then 4-metres. The Duration Rig consisted of a rotating drum 
to prevent aerosol settling, with the participants connected to the system via external tubing 
and mouthpiece (Knibbs et al. 2014; Johnson et al. 2016). Three tests were undertaken with 
the Duration Rig; participants performed 2-min of tidal breathing of HEPA-filtered air and then 
coughed for 2-min, expelling the aerosol directly into the drum. The drum was then sealed and 
the sample isolated and aged for the designated time period (5, 15 and 45-min) before aerosol 
extraction (Knibbs et al. 2014). A pump (28.3 L/min) drew the aerosol sample through six-
stage Andersen Cascade Impactors (ACI) (Thermo Scientific, Franklin, MA, USA), stacked 
with selective culture media for the target organism/s (Gram-negative bacteria [GNB]: 
chocolate bacitracin [300 mg/mL]) agar; Staphylococcus aureus: colistin nalidixic acid agar 
[Thermo Fisher Scientific Australia Pty Ltd, Victoria, Australia]). Continuous aerosol 
sampling for 5-min was undertaken during the coughing period for the distance studies and at 
the designated time following cough manoeuvres for the duration tests (Knibbs et al. 2014; 
Johnson et al. 2016). The ACI allowed particle size distribution (65µm to >7µm) of the aerosol 
samples, with droplet nuclei sized particles (≤4.7µm) collected on stages 3–6 (Andersen 1958).  
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2.3.3  Bacterial culture of sputum and aerosols 
Standard qualitative and quantitative microbiological processing was performed on sputum 
samples (Knibbs et al. 2014).  Qualitative cultures were undertaken with undigested sputum 
inoculated onto agar culture plates (Thermo Fisher (Oxoid Australia)) including horse blood 
agar (HBA), colistin nalidixic acid (CNA), chocolate-bacitracin agar (BAC), MacConkey 
(MAC), mannitol salt agar (MSA) and B. cepacia selective agar (BCSA) (BioMerieux). The 
HBA, CNA and BAC plates were incubated in 5% CO2 at 35°C for 72 hours, and the MAC, 
BCSA and MSA were incubated aerobically at 35°C for 72 hours. The qualitative count (scant to 
4+) was recorded for each organism type. 
For the quantitative culture, sputum was homogenised with Sputasol reagent (Thermo Fisher 
(Oxoid Australia)) and incubated at 37°C for at least 15 minutes. Serial dilution techniques 
were applied to the digested sputum to achieve dilutions from 10-1 to 10-6. Ten microliters of 
the neat and diluted samples were inoculated onto BAC plates for GNB and CNA for S. aureus. 
The plates were incubated in O2 at 35°C. All cultures were reviewed at 24, 48 and 72 hours. The 
quantitative count for each organism type was calculated and adjusted for the dilution factors, to 
give an overall result in CFU/mL. 
The aerosol plates were incubated aerobically at 35°C and the total number of bacterial colony 
forming units across all stages of the ACI were enumerated daily for 72 hours. Hole correction 
adjustments were made according to published equations, to account for multiple viable 
particles impacting the same site (Macher 1989). 
2.3.4  Bacterial typing 
DNA extraction of positive isolates was undertaken following the processes of the UltraClean 
Microbial DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA). Identification of the S. 
aureus isolates was performed by latex agglutination using the Staphytech Plus kit (Thermo 
Fisher Scientific Australia Pty Ltd, Victoria, Australia) and S. aureus genotyping was 
undertaken by Pathology Queensland Central Laboratory, Australia using a single nucleotide 
polymorphism-plus-binary-marker-based typing system as previously described (Huygens et 
al. 2006). Presumptive GNB identification was carried out using the VITEK® MS Mass 
spectrometry identification system (bioMérieux Australia Pty Ltd, Queensland, Australia), 
with identity confirmation and multilocus sequence typing (MLST) achieved by whole genome 
sequence (Australian Genome Research Facility, Victoria, Australia) analysis using the Centre 
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for Genomic Epidemiology Pathogen Finder (Cosentino et al. 2013) and MLST (Larsen et al. 
2012) platforms, in conjunction with the Burkholderia cepacia complex, Achromobacter and 
Stenotrophomonas maltophilia PubMLST databases (Jolley and Maiden 2010). Molecular 
typing data were used to compare the relatedness between positive aerosol and sputum isolates 
cultured from individual participants and across the study cohort.  
2.3.5   Infection control  
One participant was tested on the experimental day. Cleaning of the Rigs was undertaken daily 
at the completion of the experiments.  These were disassembled and disinfected with 0.15% 
benzalkonium chloride (GlitzTM, Pascoes Pty Ltd, Australia).  Ethanol (70%) was then applied 
to all surfaces. Circuits that connected the participant to the Duration Rig underwent heat 
disinfection and cleaning at the Central Sterilising Department, The Prince Charles Hospital. 
As a quality assurance measure of effective cleaning procedures and to ensure that there was 
no contamination carry-over between participants, a surface swab and “blank” aerosol sample 
was collected from the Distance and Duration Rig at the commencement of each experimental 
day.   
2.3.6  Statistical analysis 
Data were analysed using SPSS version 23 (IBM Corp., N.Y., USA). The experimental unit 
was organism. The total colony-forming unit (CFU) counts for sputum and aerosol plates were 
compared between GNB and S. aureus after log10 transformation for analysis and back-
transformation to the geometric mean for reporting. Where the organism was detected in 
sputum samples, a Pearson’s correlation examined correlations between clinical 
characteristics, sputum bacterial concentration and total viable aerosol at 2-metres for each of 
the GNB and S. aureus organisms detected. The 2-metre distance was selected in accordance 
with current infection control recommendations for separation between people with CF 
(Saiman et al. 2014) and correlation data for P. aeruginosa from our recent study was also 
reported as a comparison (Wood et al. 2018).  Categorical variables were examined using 
Pearson Chi-Squared or the Fisher’s Exact test when more than 20% of the expected counts 
were less than 5. Continuous variables were examined using the Student t-test and the Levene’s 
test used to check for equality of variances. 
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2.4  Results 
2.4.1                Population description 
Thirty participants (19 males (63.3%)) with mean (SD) age 29.9 (10.4) years, FEV1 61.9 (25.7) 
% predicted and BMI 23.6 (4.5) kg/m2 were studied (Table 2.1). Twelve participants had a history 
of GNB infection, twelve participants had pre-existing S. aureus infection, and 6 participants 
harboured both a GNB and S. aureus; thereby 18 participants were assigned to each organism 
group (Figure 2.1). One participant (GNB) could not tolerate or complete the 15 and 45-min 
duration experiments.  
 
Table 2.1  Participant clinical characteristics 
 
 
 
 
 
 
 
 
 
2.4.2           Sputum bacteriology 
Expectorated sputum samples were provided by 29/30 participants. Participants with negative or 
missing sputum cultures were excluded from the analysis.  Of the 18 participants with previous 
GNB infection, 18 GNB organisms were identified in sputum from 15 participants (three 
participants harboured two different GNB species): S. maltophilia, n=7; Achromobacter spp., 
n=5; Burkholderia spp., n=6 (Figure 2.1).  S. aureus was recovered from 16/18 participants 
with history of infection (Figure 2.1). The mean (95% CI) sputum bacterial concentration 
(CFU/mL x 106) for the GNB group was 7.0 (1.6 – 31) and for the S. aureus group, 1.3 (0.2 – 
7.5) (p=0.13; Table 2.2).
Characteristic 
Overall for individuals n=30 
mean (SD) 
Age (years)    29.9 (10.4) 
Sex, male (n (%))    19 (63.3) 
Height (cm)    170.9 (8.0) 
Weight (kg)    69.6 (17.0) 
BMI (kg/m2)    23.6 (4.5) 
FEV1 (litres)    2.4 (1.1) 
FEV1 % predicted    61.9 (25.7) 
FVC (litres)    3.7 (1.2) 
FVC % predicted    79.2 (21.8) 
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Table 2.2 Comparison of the sputum and aerosol concentrations between the GNB and S. aureus groups 
 
Sputum parameter; mean* (95% CI) 
Stratified by organism/s identified in sputum 
p-value 
GNB, n=18† S. aureus, n=16 
Sputum bacterial concentration;   
CFU/mL x 106 
7.0  (1.6 – 31) 1.3 (0.2  – 7.5) 0.13 
Aerosol parameter; mean* (95% CI) n# 
GNB aerosol  
CFU  
n# 
S. aureus aerosol 
CFU 
p-value  
Distance     
2-metres 14 11 (4 – 28)  9 5 (2 – 10)     0.22 
4-metres 11 20 (7 – 50)  8 7 (2 – 23)  0.14 
Duration      
5-minutes 10 13 (4 – 38)  8 3 (1 – 8)  0.062 
15-minutes ‡ 9 10 (3 – 32)  6 4 (2 – 7)  0.12 
45-minutes ‡ 9 12 (3 – 40)  4 4 (1 – 12)  0.10 
* Geometric mean  
† 18 GNB organisms identified from the sputum of 15 participants (three participants had two GNB species detected) 
‡ One GNB group participant did not complete the 15 and 45-min duration experiments 
# Target organisms identified in sputum that had a positive aerosol detected 
Definition of abbreviations: CFU, colony forming unit; CFU/mL, CFU per millilitre of sputum; CI, confidence interval; GNB, Gram-negative 
bacteria
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Figure 2.1  Flow chart of the participant stratification and matched sputum/ aerosol findings 
 
 
2.4.3  Aerosol sampling 
During the cough experiments, at least one positive aerosol was detected for 15/18 (83%) 
organisms in the GNB group and 10/16 (63%) in the S. aureus group (p=0.25). 11/18 (61%) GNB 
organisms were cultured at 4-metres, and 9/17 (53%) at 45-min; whereas for the S. aureus group, 
8/16 (50.0%) had viable aerosol at 4-metres and 4/16 (25%) at 45-min, with no significant 
difference in the number of bacterial CFUs between the groups at any distance or duration (Table 
2.4).  At 2-metres, the mean percentage of viable particles cultured in the droplet nuclei size 
range (≤4.7µm) was 66.5 (SD 26.1) for the GNB organism group and 58.2 (SD 26.0) for the S. 
aureus group (p=0.46; Table 2.3). There were no statistically significant differences in the 
percentage of particles in the respirable range between those in the GNB and S. aureus groups 
in any of the distance and duration experiments (Table 2.3).  
CF pathogens were not identified on any of the blank aerosol samples or surface swabs 
collected as part of the quality assurance, confirming that cleaning methods were adequate and 
that there was no carry over between patient tests. 
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Table 2.3  Comparison of the percentage of particles in respirable range between GNB and S. 
aureus groups. 
 
Parameter % Particles in respirable range p-value 
 Gram-negative bacteria Staphylococcus aureus  
  mean (SD) mean (SD)   
Distance    
2-metres n=14 n=9  
 
 
66.5 (26.1) 58.2 (26.0) 0.46 
4-metres n=11 n=8  
 
 
59.4 (25.4) 63.5 (35.1) 0.77 
Duration    
5-minutes n=10 n=8  
 
 
92.6 (14.0) 84.7 (35.1) 0.52 
15-minutes n=9 n=6  
 
 
97.5 (4.8) 88.3 (20.4) 0.33 
45-minutes n=9 n=4  
  
 
94.4 (16.6) 92.3 (9.0) 0.82 
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2.4.4  Sputum and aerosol bacterial typing 
Fourteen viable GNB cultures were detected in cough aerosols from 13 participants (Figure 
2.1) and each organism had an identical genotype identified in paired sputum (confirmed by 
MLST-derived from whole genome sequences) including: S. maltophilia (n=6); 
Achromobacter spp. (n=4); and Burkholderia spp. (n=4). Aerosolised bacteria were not 
detected for five participants in the GNB group, including the participant who did not provide 
a sputum sample. Each participant had distinct strains of GNB species. Ten of 16 participants 
had S. aureus cultured from their paired sputum and aerosol samples (Figure 2.1) and 8/10 had 
concordant genotypes. Isogenic strains were identified in the aerosol and sputum samples of 
the remaining two participants (as determined by single nucleotide polymorphism-based 
genotyping).  
2.4.5  Clinical variables and bacterial CFU correlations at 2-metres 
Bacterial sputum and aerosol concentrations were correlated for GNB species (r=0.50, 
p=0.035) and S. aureus (r=0.66, p=0.005) compared to r=0.55 (p=0.005) for P. aeruginosa. 
There was no correlation between clinical characteristics of age, FEV1 (volume and % 
predicted) and FVC (volume and % predicted) for each organism group and aerosol 
concentration at 2-metres (Table 2.4). An association between higher body mass index in the 
S. aureus group and aerosol load was found (Table 2.4). 
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Table 2.4   Correlation of participant clinical characteristics and aerosol concentration for S. aureus and GNB, at distance of 2-metres 
 
Clinical Characteristics 
 
S. aureus Gram-negative bacteria 
Correlation      p-value Correlation      p-value 
  Age (years)   -0.037       0.89   -0.209       0.38 
  Height (cm)   0.158       0.56   0.155       0.51 
  BMI (kg/m2)   0.721       0.002   -0.070       0.77 
  FEV1 (litres)   0.37       0.16   0.058       0.81 
  FEV1 % predicted   0.231       0.39   -0.114       0.63 
  FVC (litres)   0.336       0.20   0.210       0.38 
  FVC % predicted   0.147       0.59   0.030       0.90 
 
Definition of abbreviations: S. aureus, Staphylococcus aureus; GNB, Gram-negative bacteria; BMI, body mass index; FEV1, forced expiration in 1 
second 
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2.5  Discussion  
Person-to-person spread of pathogens remains a concern to the CF community, with the airborne 
route considered a potential transmission pathway (Jones et al. 2003; Wainwright et al. 2009; Bryant 
et al. 2016). This study demonstrates for the first time that GNB species and S. aureus commonly 
recovered from respiratory samples from people with CF can be aerosolised during coughing, survive 
for up to 45-min and travel up to 4-metres from the point of generation. This is similar to airborne 
characteristics previously described for P. aeruginosa and M. abscessus (Knibbs et al. 2014; Bryant 
et al. 2016).  Molecular typing of bacterial strains of paired sputum and aerosol samples from 
individuals confirm that the patients were the source of the potentially infectious aerosols. The 
majority of viable particles detected were contained within droplet-nuclei, which are of a size range 
capable of airborne dispersal and inhaled airway deposition, providing evidence that airborne 
transmission may be a factor in the acquisition of CF pathogens. 
Some of the first reports of person-to-person transmission of CF pathogens involved Burkholderia 
cepacia complex species (Isles et al. 1984; LiPuma et al. 1990; Govan et al. 1993).  The Burkholderia 
cenocepacia ET-12 strain infected CF populations in both United Kingdom and Canada, appeared to 
be highly transmissible and was associated with unfavourable clinical outcomes (Govan et al. 1993; 
Jones et al. 2004).  Epidemic outbreaks were attributed to close personal interactions within hospital 
facilities and at social gatherings, including camps and group exercise classes (LiPuma et al. 1990; 
Govan et al. 1993). Whilst contact and droplet transmission were considered likely acquisition routes, 
the possibility of airborne dispersal was postulated after studies detected positive air contamination 
with BCC in the immediate surroundings of infected inpatients. (Humphreys et al. 1994; Ensor et al. 
1996). Here we provide confirmation that viable aerosols containing Burkholderia spp. are generated 
directly from people with CF and have extended survival ability within an airborne state, thereby 
suggesting that this pathway may have a contributory role in cross-infection with BCC. 
Interestingly, person-to-person spread of other common non-P. aeruginosa CF pathogens has not 
occurred on a scale that has been observed with B. cenocepacia . Genetically identical clones of 
Achromobacter species have been recovered in some CF Centres, which is suggestive of possible 
cross-infection (Lambiase et al. 2011; Pereira et al. 2011), and one study proposed airborne dispersal 
as an acquisition route in instances where direct contact transmission was excluded (Hansen et al. 
2013).  Transmission of S. aureus and MRSA has been reported between people with CF (Schlichting 
et al. 1993; Givney et al. 1997) and suspected in relatively low frequency for S. maltophilia (Pompilio 
et al. 2011).  However, people with CF can also contaminate their immediate environment within 
hospitals (Doring et al. 1996; Zuckerman et al. 2009; Bryant et al. 2016) and common pathogens 
have been shown to have increased survival when suspended in CF sputum, thereby facilitating 
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indirect contact transmission (Doring et al. 1996; Drabick et al. 1996). Whilst the routes of acquisition 
for some of the pathogens of interest could be CF person-to-person spread, other modes of acquisition 
including contact with other infected patients, and/or the healthcare environment and/or healthcare 
professionals may also be important (Kidd et al. 2006; Ridderberg et al. 2011; Muhlebach et al. 2015; 
Wood et al. 2016).  However, the detection of S. maltophilia, Achromobacter spp. and S. aureus 
within cough-generated aerosols in the current study at 45-minutes and 4-metres suggests that 
airborne dispersal is also a possible route of cross-infection. While the precise factors that influence 
whether an organism is acquired and retained by some patients and not others are unknown, the 
presence of an organism to persist within the aerosol state infers its ability to be transmitted by this 
pathway. It is likely that the acquisition pathways of each of these bacteria are complex and may 
include interspecies differences in ability to be transmitted from one source to another. Factors such 
as innate characteristics, host susceptibility and environmental elements may all be important 
determinants. Increased temperature and reduced humidity are known to impact the aerosol survival 
of P. aeruginosa, as demonstrated during in-vitro studies (Clifton et al. 2008). Further studies are 
required to better understand the transmission mechanisms of each bacteria so as to allow refinement 
in infection control practices, especially as many of these pathogens have multi-antibiotic resistant 
profiles and pose a risk to all individuals with CF.  
We observed heterogeneity in the magnitude of viable bacterial aerosol production from participants 
and sought to explore the relationship between this and clinical variables.  An association between 
aerosol and sputum bacterial concentrations for GNB and S. aureus was demonstrated, which is 
consistent with findings in earlier cough aerosol studies for P. aeruginosa (Wainwright et al. 2009; 
Knibbs et al. 2014; Wood et al. 2018). This suggests that individuals with CF that have a higher 
burden of microbial load in the sputum may  disperse a larger infectious reservoir into the immediate 
surrounding air during coughing and hypothetically provide a greater risk for airborne transmission.  
These findings may have important implications for infection control within communal areas of 
hospital facilities where people with CF may be (often unknowingly) within close proximity or with 
shared air-supply, such as waiting areas or cafeterias.  
Other clinical characteristics of age, FEV1 (volume and % predicted) and FVC (volume and % 
predicted) did not show an association with aerosol concentration in either organism group at 2-
metres.  However, Wainwright et al. previously used a sampling device that enumerated viable 
aerosols directly from the coughing individual and found a positive correlation between FEV1 volume 
and cough aerosol production, suggesting that those with mild lung disease may pose a greater 
infectious risk (Wainwright et al. 2009). The difference in the findings of these two studies may be 
explained by the 2-metre sampling distance in the present study; this may have resulted in lower 
39 
 
aerosol concentrations due to early and rapid biological decay, which is known to occur within the 
first 10 seconds for aerosols containing P. aeruginosa (Johnson et al. 2016). Cough strength was not 
objectively measured in the current study and consideration should be given to evaluating this in 
future work, although cough strength measures can be challenging due to the invasive nature of some 
techniques (e.g oesophageal pressure) (Man et al. 2003). Cough auditory tone may have greater 
clinical utility, with a recent study showing a relationship between cough sound and cough strength 
(Lee et al. 2017). Overall, these data suggest that routine clinical measurements for people with CF 
do not predict the aerosol generating potential of an individual. Quantitative sputum bacterial counts 
are not routinely undertaken in CF clinical facilities and therefore identifying features to determine 
which individuals may be large aerosol producers within a CF clinic are not readily available. Taken 
together, these findings provide further support for the recommendation of universal precautions and 
the use of surgical masks to minimise potential cross-infection within healthcare facilities for all 
individuals with CF (Wood et al. 2018).   
There are a number of limitations to this study.  First, the dose to establish infection is unknown in 
individuals with CF for each of the bacteria tested and therefore it is not possible to quantify 
individual risk of transmission via the airborne route. Furthermore, reduced humidity and increased 
temperature are known to influence rates of aerosol desiccation. Our findings reflect controlled 
environmental conditions within a laboratory setting and may not represent a hospital ward or 
outpatient clinic environment. As well, direct evidence of cross-infection by airborne transmission is 
not available, and it would be unethical to conduct such experiments by exposing uninfected patients 
to bacteria.   
Second, the study group had moderate lung disease and included mostly an adult cohort. Therefore 
implications for younger children remains undetermined and our findings may not be representative 
for all people with CF. The infectious transmission risk of M. tuberculosis is lower in the infected 
paediatric population compared to adults, which is thought due to paucibacillary disease and reduced 
cough strength (Piccini et al. 2014). Whether an age difference in infectious aerosol production occurs 
in people with CF is yet to be extensively explored. .  Three of the four adolescents in this study 
(mean (range) FEV1 70.5 (56.9 – 104.5) % predicted) did not produce viable aerosol, including the 
participant who was unable to provide an expectorated sputum sample. However, earlier studies have 
demonstrated that non-producers of sputum can generate aerosols with detectable bacteria and 
therefore remain a potential transmission risk (Wainwright et al. 2009). Further studies are required 
to address whether infectious aerosols are produced by people with CF in the setting of preserved 
lung function and/or non-productive of sputum.  
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This study has demonstrated that common CF pathogens can be aerosolised during coughing and 
survive within droplet nuclei for extended durations. Viable particles of this size range can potentially 
remain suspended for prolonged periods and are capable of travel large distances depending on air 
currents and flow. This provides evidence that airborne transmission may be plausible for the 
organisms tested.  Individuals with CF are heterogeneous producers of potentially infectious aerosols 
and the only predictor of the magnitude of viable aerosols was quantitative sputum bacterial load, 
which is not a standard analyses undertaken within CF clinical settings.  In conclusion, these data 
reinforce the importance of a universal approach to infection control practices for all people with CF.  
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Chapter 3:  Cough aerosolisation of Mycobacterium abscessus 
3.1  Abstract 
Rationale: Increasing rates of non-tuberculous mycobacteria (NTM) respiratory infection in 
individuals with CF have been reported over the last decade. The species Mycobacterium abscessus 
is of particular clinical concern to CF Centres because of the possible risk of cross-infection, although 
the mechanisms of transmission are not clearly understood.  
Objective: To investigate the feasibility of aerosolisation of M. abscessus during coughing in people 
with CF and active respiratory infection. 
Methods:  Three participants with a diagnosis of CF and recent M. abscessus infection were enrolled.  
Validated aerosol sampling equipment measured the distance and duration of viable cough generated 
aerosols and an Andersen Cascade Impactor provided size distribution of M. abscessus aerosol 
particles. Molecular typing of M. abscessus isolates was undertaken to determine genetic relatedness 
of individuals’ paired sputum and aerosol samples. 
Measurements and Main Results: One participant produced cough aerosols that were culture positive 
for M. abscessus at 2 and 4-metres and 5, 15 and 45-minutes. The paired sputum sample was smear 
positive for AFBs and whole genome sequencing confirmed that the sputum M. abscessus isolate was 
genetically indistinguishable to the M. abscessus isolates of the aerosol samples. One M. abscessus 
isolate (presumably a fomite) was detected at 24 hours. The remaining two participants (one of whom 
was M. abscessus culture positive on sputum) did not produce aerosol with detectable M. abscessus. 
Conclusions:  During coughing, M. abscessus can be aerosolised as droplet nuclei (≤4.7um in 
diameter), travel up to 4-metres and remain viable for up to 45-minutes.  Viable M. abscessus was 
evident at 24 hours.  Airborne transmission of M. abscessus is plausible.  
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3.2  Introduction 
Mycobacteria are classified into three groups: Mycobacterium tuberculosis complex, Mycobacterium 
leprae and non-tuberculous mycobacteria.  Non-tuberculous mycobacteria (NTM) are ubiquitous 
environmental organisms that can cause opportunistic infection in many body systems of humans, 
particularly those with pre-existing lung disease and in patients who are systemically 
immunocompromised. Pulmonary manifestations are the most common in people with cystic fibrosis 
(CF).  NTM are considered emerging pathogens in CF, with reports of increased prevalence in 
respiratory samples over the last decade (Cystic Fibrosis Foundation 2017). Two NTM species are 
responsible for the majority of infections in people with CF, although the major pathogen varies with 
geographical location. The slow-growing species Mycobacterium avium complex is the predominant 
species reported in patients with CF in USA (Olivier et al. 2003; Cystic Fibrosis Foundation 2017), 
whereas the rapid-growing Mycobacterium abscessus complex (comprising M. abscessus subspecies 
abscessus, M. abscessus subsp. massiliense and M. abscessus subsp. bolletii) are more commonly 
recovered from CF populations in Europe (Roux et al. 2009; Qvist et al. 2015), Israel (Bar-On et al. 
2015) and areas of Australia (Sherrard et al. 2017).  
Whilst Mycobacterium tuberculosis is highly transmissible between humans by the airborne route, 
person-to-person transmission of NTM species was thought not to occur (Olivier et al. 2003). 
However, recent evidence has suggested cross-infection with M. abscessus within and across CF 
Centres. Separate respiratory outbreaks of M. abscessus were reported in two CF Centres, despite 
adherence to strict infection control measures that minimised the potential for droplet and direct 
contact transmission between patients (Aitken et al. 2012; Bryant et al. 2013).  Cross-infection by 
indirect methods of infectious aerosols or fomites was suspected in these reports.  
An international epidemiological study utilised whole-genome sequencing to assess genetic 
relatedness of M. abscessus respiratory isolates from patients with CF from different continents 
(Bryant et al. 2016).  Queensland-derived stored isolates contributed to this global analysis, with 
permission and collaboration with the Queensland Mycobacterial Reference Laboratory (QMRL). 
Whilst the study demonstrated common circulating M. abscessus clones consistent with cross-
infection, the mechanisms of transmission of M. abscessus are not clearly understood and potential 
routes have not been studied extensively.  This study provided an opportunity to investigate if patients 
with CF and active M. abscessus respiratory infection could aerosolise the organism during coughing 
and to determine the particle size distribution and viability of aerosolised M. abscessus.  
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3.3  Methods 
3.3.1  Participants 
Participants with a diagnosis of CF and active (current) M. abscessus infection attending the Adult 
CF Centre, The Prince Charles Hospital, Brisbane were enrolled into the study in 2015. Participants 
performed spirometry according to ATS Standards (Miller et al. 2005) on the experimental day and 
height and weight were measured.  An expectorated sputum sample was collected for bacteriological 
and mycobacterial culture. 
3.3.2   Cough aerosol collection 
Participants performed five cough studies on a single experimental day. The study utilised two 
validated cough aerosol sampling devices as previously described (Chapter 2); the Distance Rig and 
the Duration Rig (Knibbs et al. 2014; Johnson et al. 2016). Both systems utilised HEPA-filtered air 
to washout circulating room air and reduce environmental contamination. 
For each study, participants undertook two minutes of tidal breathing before being requested to cough 
at a comfortable frequency and strength for: 1) 5-min in the Distance Rig and; 2) 2-min into the 
Duration Rig. Aerosols from both rigs were collected for 5-min through a six-stage Andersen Cascade 
Impactor (ACI) (Andersen 1958) which was stacked with petri dishes containing Middlebrook 7H11 
culture media, supplemented with oleic acid-albumin-dextrose-catalase enrichment (100 mL/L), 
malachite green (25mg/L) and cycloheximide (Thomson et al. 2013) prepared by Pathology 
Queensland Media Department, Brisbane.  The ACI has been used previously to investigate 
mycobacterial cough aerosols from patients (Fennelly et al. 2004) and provides size distribution of 
viable aerosols in the ranges of <0.65 µm to >7µm, with airborne particles of a respirable size 
(≤4.7µm) represented by cultures on media in stages 3 – 6 (Andersen 1958). 
One participant was tested on each experimental day. Both Rigs were cleaned at the completion of 
the five cough experiments for each individual with a disinfection process comprising 0.15% 
benzalkonium chloride (GlitzTM, Pascoes Pty Ltd, Australia) and application of 70% ethanol to all 
surfaces, as guided by The Prince Charles Hospital (TPCH) Infection Control and Infection 
Prevention team. The Rigs were reassembled and dried overnight with HEPA-filtered air.  Tubing 
from the Duration Rig was heat sterilised at the Central Sterilising Department, TPCH.  Equipment 
unable to withstand heat disinfection was cleaned with a multienzymatic detergent, Asepti Release 
Plus (Ecolab), immersed into diluted Milton (50mLs/ 4 litres) for 20 minutes and thoroughly sprayed 
with 70% ethanol before air-drying.  All components of the Andersen Cascade Impactors were 
cleaned with 70% ethanol.  
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A blank aerosol sample was collected from both Rigs the day following (24 hours) the experiments.  
This involved 5-min of sampling through the ACI from the Distance Rig at 2-metres and from the 
Duration Rig.   
3.3.3   Microbiological analysis 
3.3.3.1  Sputum and aerosol samples 
Sputum and aerosol sample analysis was performed by QMRL, Brisbane, Australia. In brief, using 
the standard protocol for NTM cultures, sputum samples were decontaminated using 4% Sodium 
Hydroxide and neutralised with 1 M phosphoric acid solution. Staining via the Ziehl-Neelsen (ZN) 
method was performed to detect acid-fast bacilli (AFB). Samples were inoculated onto Lowenstein-
Jensen slopes containing pyruvate and a 7mL Mycobacteria Growth Indicator Tube (MGIT) with 
OADC enrichment and PANTA (Polymixin B, Amphotericin, Naladixic Acid, Trimethoprim and 
Azlocillin) (Becton Dickinson, North Ryde, NSW) and incubated at 35°C for six weeks.  The aerosol 
plates were incubated at 35°C and reviewed weekly to count colony forming units (CFU) and 
subcultured onto purity plates.  
All bacterial samples were sub-cultured onto solid media. DNA extraction of AFB positive isolates 
from the sputum and cough aerosols were extracted using the UltraClean Microbial DNA Isolation 
Kit (Mo Bio Laboratories, Carlsbad, CA). This work was performed in the Lung Bacteria Laboratory 
at QIMR Berghofer Medical Research Institute. Extracted genomic DNA of representative  
M. abscessus isolates were transported to the Sanger Institute (Cambridge, United Kingdom) for 
whole genome sequence analysis. The DNA samples were then subjected to multiplexed paired-end 
sequencing using the Illumina Hiseq platform at the Sanger Institute (Cambridge, UK).  
3.3.3.2  Bioinformatic analysis 
Reads were mapped using SMALT (Ponstingl) to three different reference sequences (ATCC19977 
(Ripoll et al. 2009) and M. abscessus subsp. massiliense and M. abscessus subsp. bolletii de-novo 
assemblies described previously (Bryant et al. 2013), representing the three-different subspecies. 
Variant calling, phylogenetic analyses and clustering were performed by Dr Josie Bryant at Sanger 
Institute as a part of an extensive analysis of 1173 M. abscessus isolates comprising a global study 
published in 2016 (Bryant et al. 2016).  In summary, multiplexed paired end sequencing was 
performed on the sputum and aerosol isolates recovered from Case 3, to determine genetic 
relatedness, using established methods (Bryant et al. 2013) with Bayesian inference implemented in 
BEAST v1.7.5. 
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3.4  Results 
Three participants with CF and M. abscessus infection were enrolled to the study, as follows:  
Case 1: A 52 year male with CF (genotype F508del/F508del) and chronic M. abscessus infection for 
8 years. He had severe lung disease with an FEV1 of 31% predicted. The sputum sample collected on 
the experimental day was AFB smear negative but culture positive for M. abscessus.  M. abscessus 
was not detected in any aerosols of any cough test.    
 
Case 2: A 28 year old female with CF (genotype F508del/R560T) and moderate lung disease (FEV1 
48% predicted).  She had an initial isolation of M. abscessus five months prior to the study. During 
this period, four clinical sputum samples were analysed; all were AFB smear negative and three of 
the four sputum samples were culture positive for M. abscessus (the most recent being 30 days before 
study participation). The patient undertook the cough aerosol study on the day prior to commencing 
M. abscessus IV eradication therapy.  The sputum sample was AFB negative and culture negative for 
M. abscessus.  M. abscessus was not detected in aerosols collected at any distance or duration.  
Case 3:  A 17 year old male with CF (genotype F508del/unknown) and chronic history of  
M. abscessus infection for four years.  He had mild lung disease with an FEV1 79% predicted. After 
initial isolation of M. abscessus he had received induction, parenteral antibiotics targeted to eradicate, 
followed by consolidation therapy which was unsuccessful. He continued to have evidence of chronic 
infection at the time of study participation.  On the study day, a spontaneously expectorated sputum 
sample was smear positive AFB 2+ on ZN stain, and culture positive for M. abscessus.  
Aerosol isolates positive for M. abscessus were detected from the samples collected in the Distance 
Rig at 2 and 4-metres and at all durations of 5, 15 and 45-min (Figure 3.1). The majority of the  
M. abscessus isolates were detected on stages 3 – 6 of the ACI (≤4.7µm) (Table 3.1).  Aerosol 
sampling at 24 hours recovered one CFU that was positive for M. abscessus from the Distance Rig at 
2-metres.  
Whole genome sequencing identified M. abscessus subsp. massiliense in the isolates from the sputum 
and aerosol samples and confirmed that these were genetically indistinguishable. Longitudinal 
clinical respiratory samples positive for M. abscessus (bronchoscopy and sputum) collected from the 
patient between 2011 and 2014 were also analysed and compared to the cough study isolates; this 
showed small single nucleotide polymorphism (SNP) differences amongst all isolates (Figure 3.2) 
confirming the cough aerosols were generated from the subject and indicating a high degree of  
M. abscessus genetic relatedness over several years.  
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         Figure 3.1  Sputum and aerosol results of the three participants 
 
 
 
Table 3.1  Details of positive M. abscessus aerosol results for Case 3 
Aerosol sampling Total number of M. abscessus CFU 
from all stages of ACI 
Stage of ACI * that M. abscessus 
isolates were detected 
2 metres 3 
 
4 
4 metres 4 
 
1, 2, 4, 5 
5 minutes 1 
 
4 
15 minutes 5 
 
2, 3, 4 
45 minutes 4 
 
3, 5, 6 
24 hours 1  
 
6 
* Lower limit particle size range (microns) of each stage of the ACI: stage 1: 7.0; stage 2: 4.7; stage 
3: 3.3; stage 4: 2.1; stage 5: 1.1; stage 6: 0.65 
Definition of abbreviations: ACI, Andersen Cascade Impactor; CFU, colony forming units 
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Figure 3.2   A) White, yellow and orange dots represent longitudinal M. abscessus clinical samples 
from Case 3, collected at bronchoscopy (2011) and from sputum samples (2014 and 2015). Blue and 
green dots depict viable cough aerosols positive for at least one CFU of M. abscessus, at each distance 
and duration test. The red dot reflects a positive sample detected at 24-hours after the initial cough 
test; this was presumably a fomite. B) Phylogeny tree demonstrating a high degree of genetic 
relatedness (maximum of 4 SNP difference between two samples) of M. abscessus positive clinical 
and cough aerosol samples.  
 
                         
From Bryant et al., (2016). Supplementary material for Emergence and spread of a human-
transmissible multidrug-resistant nontuberculous mycobacterium. Science 354(6313): 751-757. 
Reproduced with permission from AAAS. 
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3.5  Discussion 
An in-vitro model system recently demonstrated that clinical strains of M. abscessus could survive 
within airborne sized aerosols during nebulisation (Fletcher et al. 2016). Notably, the current study 
is the first to our knowledge to demonstrate that M. abscessus can be aerosolised directly during 
coughing by patients with CF and active infection.  M. abscessus was cultured from aerosols up to 4-
metres from the source and up to 45-min after coughing, with the majority of viable particles detected 
within a respirable size range and therefore capable of being inhaled.  These data raise the possibility 
of airborne transmission of M. abscessus. Whilst all participants had evidence of chronic M. abscessus 
infection (and two with culture positive sputum samples on the experimental day), only one produced 
viable aerosol.  The infectivity of M. tuberculosis has been associated with AFB positive sputum 
smear microscopy (Sepkowitz 1996). Importantly, the participant that cultured M. abscessus in 
aerosols had a positive ZN smear (2+), suggesting that a greater organism burden may increase the 
risk of an individual’s infectiousness and transmissibility.   
Lung disease associated with M. abscessus infection is an increasing concern to the CF community 
due to its potential to cause irreversible clinical deterioration in lung function (Esther et al. 2010; Bar-
On et al. 2015) and compromise successful lung transplantation (Sanguinetti et al. 2001). 
Furthermore, M. abscessus has a multi-antibiotic resistant profile and treatment regimens are 
complicated, burdensome, often associated with side-effects and have low sputum conversion rates 
(Griffith et al. 2007; Bar-On et al. 2015).  An understanding of the potential modes of transmission 
of this organism is critical to minimising the risk of acquisition.  
M. abscessus are widespread within soil and water and these were considered the likely source of 
acquisition.  Whilst studies have detected NTM species within tap water supplies (Engel et al. 1980; 
Mankiewicz and Majdaniw 1982) and hospital water systems (Tobin-D'Angelo et al. 2004), these do 
not mention isolation of M. abscessus.  Locally, Thomson and colleagues highlighted a strong case 
for environmental acquisition of M. abscessus when they demonstrated that this species could be 
recovered from Queensland town water distribution supplies (Thomson et al. 2013).  Their 
subsequent study using a rep-PCR based typing methodology found close genetic relatedness between 
M. abscessus isolates detected in Brisbane potable water and respiratory isolates of people with non-
CF respiratory disease living in similar geographical locations to the areas sampled (Thomson et al. 
2013). Furthermore, M. abscessus cultures generated from shower aerosols were within the respirable 
size range when collected in a six-stage ACI, thereby providing a potential route of acquisition of 
pulmonary infection from the environment (Thomson et al. 2013).  The findings of the current in-
vivo study provide further evidence that people with active M. abscessus infection can aerosolise 
49 
 
viable pathogen during coughing and therefore cross-infection by the airborne route may also be an 
important acquisition source within hospital environments.   
Person-to-person transmission of M. abscessus subsp. massiliense has been described. A Seattle CF 
clinic reported an outbreak of M. abscessus in their outpatient clinic; a patient with chronic  
M. abscessus infection and high microbial load (sputum AFB smear positive 4+) was considered the 
infectious source in transmission to four other patients (Aitken et al. 2012).  Although no known 
direct contact occurred between the patients, there were overlapping outpatient clinic day attendances 
and opportunity for indirect transmission by contaminated surfaces or airborne aerosols. Clinical 
epidemiological investigation of an outbreak of M. abscessus at the Papworth CF Centre, UK revealed 
positive environmental samples from an inpatient room habited by a person with chronic M. abscessus 
infection and others who  subsequently acquired infection with a genetically indistinguishable strain 
(Bryant et al. 2016). M. abscessus was isolated at multiple time points from surfaces within the 
inpatient setting, suggesting that the infectious patient may have contaminated their immediate 
environment and that standard cleaning procedures were inadequate. Indeed, our findings support the 
long term survival of M. abscessus within fomites. Based on some of their earlier work, Bryant et al. 
also proposed that M. abscessus subsp. massiliense may have increased transmissibility compared to 
other M. abscessus subspecies (Bryant et al. 2013). Interestingly, in our study, M. abscessus subsp. 
massiliense was the strain that was identified in the one individual that produced viable aerosols.  
Whilst a number of studies have found no evidence of cross-infection of M. abscessus within their 
CF Centres (Bange et al. 2001; Harris et al. 2015; O'Driscoll et al. 2016), a recent international study 
of clinical isolates from people with CF undertaken by Bryant et al. described genetically related 
global circulating clones of M. abscessus in geographically diverse locations including UK, Australia, 
Europe and North America, suggesting person-to-person transmission on a large scale (Bryant et al. 
2016). The actual modes of transmission were undetermined, especially as there was no evidence of 
patient or equipment movement across continents (Bryant et al. 2016). The data from the current 
study highlight the potential of cross-infection by both aerosol dispersal and indirect transmission by 
fomites.  
Detection of a positive M. abscessus isolate at 24-hours after disinfection and cleaning of the testing 
equipment suggests its capability to survive for extended periods as a fomite.  M. abscessus is known 
to be a hardy organism that can persist in hospitals and is resistant to disinfectants and desiccation 
(Wallace et al. 1998). CF Centres have reported that outbreaks of M. abscessus have been contained 
with no further evidence of person-to-person spread implementing strategies including: additional 
cleaning methods and healthcare professional/ patient education (Kapnadak et al. 2016),  negative 
pressure ventilation rooms for inpatients (Bryant et al. 2013) and airborne isolation rooms for 
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outpatients (Aitken et al. 2012). Therefore, additional precautions even more stringent for  
M. abscessus may need to be applied to current CF infection control guidelines to minimise potential 
for acquisition and transmission (Kapnadak et al. 2016). 
The current study has a number of limitations. Firstly, the natural environmental genetic diversity of 
M. abscessus and spontaneous mutation rate are not known. Therefore, further epidemiological work 
is required to investigate possible common environmental sources (Strong and Davidson 2017), as 
has been observed with other epidemic CF pathogens such as the P. aeruginosa Clone C strain. Whilst 
a small number of bacteria is considered sufficient to establish M. tuberculosis infection in a 
vulnerable human host (Riley 1957; Riley et al. 1962), the infectious dose of M. abscessus in 
susceptible patients of is not known. However, it has been suggested that a low inoculum may be 
sufficient for M. abscessus to establish infection (Bryant et al. 2013).  Additionally, the individual 
that produced viable aerosol in the current study was not receiving eradication or suppressive therapy 
at the time of study participation, and this may also influence the level of infectivity, Therefore, 
although this study has demonstrated that M. abscessus can persist within droplet nuclei which are of 
a particle size that can be inhaled, it is not possible to quantify the airborne transmission risk 
associated with coughing. Importantly, it has recently been reported that high CFU counts (≥10) of 
M. tuberculosis in aerosols from infected patients was a better predictor of transmission and new 
infection in close contacts than microscopy smear and culture (Fennelly et al. 2012; Jones-Lopez et 
al. 2013).  In view of the identification of M. abscessus in a delayed positive sample  24-hours after 
the prior study, the investigator group decided to suspend recruitment until the potential source of 
infection was understood, so as to reduce any risk of cross-infection. No adverse events (unexpected 
new cases of M. abscessus infection) were detected and consequently, due to low participant numbers 
we were unable to perform any statistical analyses to determine if any clinical or demographic 
variables were predictive of the concentration of cough aerosol, as has been previously documented 
(Knibbs et al. 2014).  Further studies are required to investigate these aspects, so as to better inform 
CF infection control guidelines. 
This is the first study to have examined and provided proof of concept that M. abscessus can be 
aerosolised during cough manoeuvres in patients with CF. The study has provided information 
regarding the particle size distribution of aerosolised M. abscessus and strengthens the possibility of 
airborne transmission.  Furthermore, these data provide evidence that the survival of M. abscessus is 
prolonged within cough aerosols and may withstand conventional cleaning methods.  So as to 
minimise any risk of acquisition of M. abscessus to CF populations, further studies are required to 
investigate effective methods of decontamination for aerosolised M. abscessus and cleaning 
procedures of surfaces following hospitalisation by a person with CF who has M. abscessus infection. 
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Chapter 4: The effectiveness of face masks and cough etiquette to reduce the cough aerosol 
concentration of Pseudomonas aeruginosa in people with cystic fibrosis 
4.1   Abstract   
Rationale: People with cystic fibrosis (CF) generate Pseudomonas aeruginosa in droplet nuclei 
during coughing. The use of surgical masks has been recommended in healthcare settings to minimise 
pathogen transmission between CF patients.  
Objective: To determine if face masks and cough etiquette reduce viable P. aeruginosa aerosolised 
during cough.   
Methods: Twenty-five adults with CF and chronic P. aeruginosa infection were recruited. 
Participants performed six talking and coughing manoeuvres, with or without face masks (surgical 
and N95) and hand covering the mouth when coughing (cough etiquette) in an aerosol-sampling 
device. An Andersen Cascade Impactor sampled the aerosol at 2-metres from each participant. 
Quantitative sputum and aerosol bacterial cultures were performed and participants rated the mask 
comfort levels during the cough manoeuvres. 
Measurements and Main Results: During uncovered coughing (reference manoeuvre), 19/25 (76%) 
participants produced aerosols containing P. aeruginosa, with a positive correlation found between 
sputum P. aeruginosa concentration (CFU/mL) and aerosol P. aeruginosa CFUs. There was a 
reduction in aerosol P. aeruginosa load during coughing with surgical mask, coughing with N95 
mask and cough etiquette compared with uncovered coughing (p<0.001). A similar reduction in total 
CFUs was observed for both masks during coughing, yet participants rated surgical masks more 
comfortable (p=0.013). Cough etiquette provided approximately half the reduction of viable aerosols 
of the mask interventions during voluntary cough. Talking was a low viable aerosol producing 
activity. 
Conclusions: Face masks reduce cough generated P. aeruginosa aerosols, with the surgical mask 
providing enhanced comfort. Cough etiquette was less effective at reducing viable aerosols.  
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4.2   Introduction 
Pseudomonas aeruginosa is the dominant pathogen in the airways of people with cystic fibrosis (CF), 
with a prevalence of up to 70% in adults (Ramsay et al. 2016; Cystic Fibrosis Australia 2017; Cystic 
Fibrosis Foundation 2017). Chronic P. aeruginosa infection is associated with pulmonary function 
decline, increased exacerbations, poorer health-related quality of life and reduced survival (Kosorok 
et al. 2001; Nixon et al. 2001; Emerson et al. 2002). Studies have demonstrated that unrelated people 
with CF can harbor genetically indistinguishable strains, suggesting person-to-person spread of P. 
aeruginosa (Cheng et al. 1996; Jones et al. 2001; Armstrong et al. 2002; Aaron et al. 2010; Kidd et 
al. 2013). Consequently, CF infection control guidelines published in 2003 sought to minimise 
potential contact and droplet transmission of pathogens and recommended cohort segregation 
according to microbiological status, single room inpatient accommodation and a separation distance 
of 1-meter between people with CF (Saiman et al. 2003). Although such measures are thought to have 
contributed to a reduction in epidemic P. aeruginosa (Griffiths et al. 2005) and Burkholderia 
cenocepacia strain acquisition (France et al. 2008), cross-infection with CF pathogens has continued 
(Ridderberg et al. 2012; Kidd et al. 2013; Bryant et al. 2016). 
Airborne transmission of P. aeruginosa was first suggested as a possible mode of cross-infection by 
studies that assessed environmental air contamination in CF clinical care settings (Jones et al. 2003) 
and cough aerosols from people with CF (Wainwright et al. 2009). Particle size diameter is used to 
categorize respiratory aerosols into droplets (>5µm) and droplet nuclei (≤5µm); with the latter a 
consequence of droplet evaporation and capable of airborne transmission (World Health Organization 
2014). Our earlier work demonstrated that cough generated droplet nuclei containing P. aeruginosa 
in the respirable size range remained viable for up to 45-minutes and were detected up to 4-metres 
from the source (Knibbs et al. 2014). The updated CF infection control guidelines published in 2014 
recommended a separation distance of 2-metres and included the specific recommendation for people 
with CF to wear a surgical mask in communal areas of healthcare facilities (Saiman et al. 2014). 
Face masks and cough etiquette (i.e. coughing into the hand or arm) are strategies that may interrupt 
aerosol dispersal. The primary role of the surgical mask is to prevent contamination of the 
environment by infectious droplets. The relatively low efficiency capture of aerosols, particularly 
during cough, and incomplete seal may allow particles to escape around the perimeter (Patel et al. 
2016). The N95 mask provides inward protection from inhaled airborne pathogens, and it is 
reasonable to also expect limitation of aerosolised infectious material generated by the wearer. To 
date there is limited evidence of outward protection by surgical and N95 masks and the tolerability 
of these interventions has not been widely studied in patients with lung disease. Therefore, this study 
aimed to determine and compare the effectiveness and comfort of two commonly utilized face masks 
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and cough etiquette on dispersal of aerosolised P. aeruginosa during talking and coughing in adults 
with CF.  
4.3  Methods   
4.3.1  Participants 
 Participants (n=25) were recruited from The Prince Charles Hospital (TPCH) Adult Cystic Fibrosis 
Centre (ACFC), Brisbane, Australia in 2015. Eligible participants had a confirmed CF diagnosis, aged 
>18 years and chronic P. aeruginosa infection as determined by modified Leed’s criteria (Ramsay et 
al. 2016). Exclusion criteria comprised recent haemoptysis (>50ml), pneumothorax, pregnancy and 
cough syncope.  
4.3.2  Aerosol sampling system 
Our system comprised a unidirectional high efficiency particulate air (HEPA)-filtered flow that 
transported cough aerosols to the sampling point; its development and validation are described 
elsewhere (Johnson et al. 2016).  Viable aerosols were collected at 2-metres from participants; the 
sampling distance was defined in accordance with the current US CFF Infection Prevention and 
Control Guidelines recommending 2-metres between-person separation (Saiman et al. 2014). A pump 
extracted the aerosol samples at 28.3L/min through a six-stage (aerosol particle diameter size 65µm 
– >7µm) Andersen Cascade Impactor (ACI) stacked with selective culture media for P. aeruginosa. 
Seated participants positioned their head within the tunnel with a weighted material cover rested over 
the shoulders and a slight positive tunnel pressure to prevent room air contamination (Knibbs et al. 
2014).  
4.3.3  Aerosol sampling protocol 
Participants completed six manoeuvres on a single day: 1) talking; 2) talking wearing a tied surgical 
mask (Kimberley-Clark TECNOL Fluidshield Fog-Free Surgical Mask, Georgia, USA); 3) uncovered 
coughing (reference manoeuvre); 4) coughing wearing a tied surgical mask; 5) coughing wearing an 
N95 mask (Kimberley-Clark N95 Particulate Filter Respirator, NSW, Australia); 6) coughing with 
their hand covering their mouth (cough etiquette). The testing order of the uncovered cough 
manoeuvre, coughing wearing a surgical mask and coughing wearing an N95 mask were randomised 
to minimise potential bias in aerosol production resulting from fatigue and airway clearance with 
repeated coughing (Driessche et al. 2013). For logistical reasons, the cough etiquette test was the final 
manoeuvre performed and participants were asked to adopt their usual mouth covering technique (a 
glove was worn on the cough covering hand to minimise microbial dispersal from skin). Counting 
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using a normal conversational voice was used during the talking manoeuvres to standardise the 
approach between participants. For the cough manoeuvres, participants were instructed to cough as 
strongly as possible within comfort during the aerosol collection period. Cough numbers were 
counted manually by study staff. Participants rested for ≥20 minutes between each manoeuvre. Face 
masks were sized and applied by a trained healthcare professional. A health care professional was 
present during testing and emergency equipment was available in case of an adverse event. 
Within the tunnel each participant completed 2-minutes of tidal breathing in high-efficiency 
particulate air (HEPA) filtered air to washout residual room air, then 5-minutes of the respective 
manoeuvre (talk/cough) during which aerosols were continuously sampled through a six-stage 
Andersen Impactor (Thermo Scientific™), followed by 2-min of tidal breathing. Participants then 
completed a 5-point comfort rating score (Gregoretti et al. 2002) and provided comments regarding 
mask wear during coughing. Masks were weighed before and immediately after each manoeuvre to 
assess the level of expired air saturation. 
4.3.4   Quality control 
To ensure that there was no between-test aerosol carry-over contamination a Lasair II-110 (Particle 
Measuring Systems, Boulder, CO) optical particle counter (OPC) device was used throughout the 
study in accordance with our earlier investigation (Knibbs et al. 2014). The OPC provides real-time 
measurement of physical particle concentration using six channels with minimum diameters ranging 
from 0.1 to 5µm and is capable of accurately detecting very low particle concentrations. The OPC 
confirmed that that the system was ‘clean’ of aerosols prior to the commencement of the next 
manoeuvre. The participant test commenced only after a concentration of <0.01 particles per cm3 
(p/cc) was confirmed by the OPC, which is a similar concentration to an ISO4 cleanroom. 
4.3.5   Infection control 
Each participant was tested on a separate experimental day.  Surface swabs from the tunnel, enriched 
with Luria-Bertani broth (Sigma-Aldrich Pty Ltd, New South Wales, Australia) and blank aerosol 
samples were collected prior to the commencement of participant testing on each study day. The 
tunnel was dis-assembled daily and disinfected with 0.15% benzalkonium chloride (GlitzTM, Pascoes 
Pty Ltd, Australia), followed by surface spraying with 70% ethanol surface spray, as recommended 
for CF patient equipment (Saiman et al. 2014). The tunnel was dried overnight with continuous 
HEPA-filtered airflow.  
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4.3.6  Clinical Measurements 
Demographic and clinical measurements were recorded, including: age, gender, body mass index 
(BMI) and intravenous antibiotic use in the week prior. A sputum sample was collected on the study 
day. Spirometry (FEV1 and FVC) was performed according to ATS/ERS standards (Miller et al. 
2005) and the Global Lung Index (GLI) predicted scale (Stanojevic et al. 2008) applied.  
4.3.7  Microbiology 
Standardized qualitative and quantitative sputum cultures were performed, as previously described 
(Knibbs et al. 2014). P. aeruginosa identification was confirmed by oxidase testing, 42°C growth and 
MALDI-TOF mass spectrometry. P. aeruginosa genotyping was undertaken using the Sequenom 
iPLEX20SNP assay, as previously described (Syrmis et al. 2014).  Chocolate bacitracin (300mg/mL) 
culture media in petri dishes was used for aerosol sampling and the plates were incubated in aerobic 
conditions at 35° C for 72 hours. Total P. aeruginosa colony forming unit (CFU) counts (across all 
stages) were calculated daily, as was the sum of the colonies from stages 3, 4, 5 and 6 (≤4.7 µm) of 
the ACI, representing the respirable sized particles.  Positive-hole correction adjustment was made to 
the P. aeruginosa CFU counts for each stage of the ACI (Macher 1989). 
4.3.8  Statistical analysis 
A sample size calculation based on our earlier work (Knibbs et al. 2014) suggested 21 patients were 
required to demonstrate a 40 percentage point reduction in the presence or absence of P. aeruginosa 
with 80% power with a two-tailed p=0.05. Therefore, 25 patients with CF and chronic P. aeruginosa 
were enrolled, allowing for 10-15% dropout to achieve a sample size of 21. SPSS version 22 was 
used for statistical analysis. Categorical variable associations were examined using Fisher’s Exact 
test. Continuous variables describing participant characteristics were examined using a Student t-test. 
Clinical and demographic variables were compared with the log transformed total P. aeruginosa 
aerosol colony forming units (CFUs) in the uncovered cough manoeuvre using a Pearson correlation 
test. The paired t-test based on log transformed CFU was used to compare each intervention 
manoeuvre with the reference manoeuvre (uncovered coughing). Results were stratified by the level 
of aerosol production as follows: participants were classed as high, low or nil viable aerosol producers 
during the uncovered cough manoeuvre using an arbitrary pre-defined total CFU of ≥10 or <10, 
respectively, accumulated across the six-stages of the ACI (Figure 4.1). The Mann-Whitney U test 
was used to examine change in mask weight. McNemar’s test was used for matched pairs to compare 
comfort scores for the two mask types. 
 
56 
 
4.4  Results 
4.4.1  Participant overview 
Twenty-five (15 male) adult participants with a mean (SD) age of 31.3 (7.8) years, FEV1 50.7 (17.4) 
% predicted and BMI 22.1 (2.8) kg/m2 were recruited (Table 4.1).  Twenty-two (88%) participants 
were on maintenance azithromycin. Eleven (44%) participants were established on chronic inhaled 
antibiotic therapy (either continuous or cycling alternate month) and the remaining 14 (56%) 
participants had been prescribed inhaled antibiotic therapy (less frequently than alternate months) in 
the 12 months prior to the study.  Eleven participants (44%) had received intravenous antibiotics in 
the week prior to their study involvement. The mean (SD) age, FEV1 % predicted and BMI of patients 
attending TPCH ACFC in 2015 was 30.7 (9.9) years, 66.7 (24.1) % predicted and 23.0 (4.2) kg/m2, 
respectively. In the preceding calendar year, of 282 patients reviewed at TPCH ACFC, 68.4% had 
chronic P. aeruginosa infection.  
                     
 
Figure 4.1 Results of the uncovered cough (reference) manoeuvre 
4.4.2   Sputum microbiology 
P. aeruginosa was cultured from the 24 sputum samples provided at a mean concentration of 6.3 x 
107 CFU/mL (95% CI, 2.6 x 107 – 15.0 x 107; Table 4.1). Genotyping identified 12 different P. 
aeruginosa strains, including five common Australian shared strains (Kidd et al. 2013); AUST-01 
(n=6), AUST-02 (n=9), AUST-06 (n=6), AUST-07 (n=3), AUST-13 (n=1), five other minor shared 
strains, and two unique strains. Eight participants harboured more than one P. aeruginosa strain; two 
different strains were detected in seven participants, while one participant was infected with three 
major Australian shared strains (AUST-01, AUST-02 and AUST-06). Other CF pathogens identified 
57 
 
in the sputum on the testing day comprised: Stenotrophomonas maltophilia (n=3), Aspergillus 
fumigatus (n=3), Haemophilus influenzae (n=1) and Burkholderia cenocepacia (n=1). Five 
participants had a history of intermittent Staphylococcus aureus in the 12 months prior to the study 
but S. aureus was not isolated from sputum of participants on the day of testing.   
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Table 4.1 Baseline demographic and clinical characteristics of the study participants  
Participant Characteristics 
 
 
 
Participants categorized according to viable Pseudomonas aeruginosa 
aerosol CFUs in the uncovered cough (reference) manoeuvre 
 All participants < 10 CFUs ≥ 10 CFUs p value* 
 (n=25)                 (n=11)                 (n=14)  
Age, years, mean (SD) 
 
31.3 (7.8) 32.4 (7.0) 30.4 (8.5) 0.53 
Sex, male, n (%) 
 
15 (60.0) 6 (54.5) 9 (64.3) 0.70 
BMI, mean (SD) 
 
22.1 (2.8) 21.8 (3.1) 22.3 (2.7) 0.70 
FEV1 % predicted, mean (SD) 
 
50.7 (17.4) 52.6 (15.8) 49.2 (19.1) 0.64 
IV antibiotics administered in previous 7 days, n (%) 
 
11 (44.0) 7 (63.6) 4 (28.6) 0.12 
Pseudomonas aeruginosa CFUs/mL x 107 in sputum, 
mean (95% CI) † ‡ 
6.3 (2.6 - 15.0) 2.0 (0.4  - 10.0) 14 (5.9 - 35.0)  
*Pairwise comparison between participants with <10 (including nil) and ≥10 viable P. aeruginosa aerosol CFUs 
†A sputum sample was provided by 24/25 participants 
‡Value is geometric mean 
Definition of abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 sec; IV, intravenous; CFU, colony forming unit; CI, 
confidence interval 
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4.4.3  Aerosol sampling 
Uncovered cough manoeuvre. Of the 25 participants, 19 (76%) produced aerosols containing 
viable P. aeruginosa in the uncovered cough manoeuvre at 2-metres (Table 4.2). The 
participant unable to produce a sputum sample, was one of the six who did not culture P. 
aeruginosa on the cough aerosol plates. Molecular typing revealed that for 16 individuals, the 
P. aeruginosa genotype(s) detected in the individual’s cough aerosols were genetically 
indistinguishable to those isolated in their matched sputum sample. Three other participants 
(two with one indistinguishable P. aeruginosa genotype in their matched aerosol/sputum 
combination; one with two indistinguishable P. aeruginosa strains in their matched 
aerosol/sputum combination) were each found to have one additional P. aeruginosa strain in 
their aerosol cultures that was not detected in their sputum. The three participants who had 
isolated S. maltophilia in their sputum also generated aerosols that grew this organism 
(confirmed by MALDI-TOF).  
When the total P. aeruginosa CFUs of uncovered cough aerosols was associated with 
demographic, clinical and microbiology parameters, a statistically significant correlation was 
identified only between log transformed sputum P. aeruginosa counts and total aerosol load 
(r=0.55, p=0.01). The mean (SD) percentage of culturable particles within the respirable size 
range (≤4.7µm, collected on Andersen stages 3 to 6) were 71% (27) in the uncovered cough 
manoeuvre and 86% (30) in the cough etiquette manoeuvre (p=0.21).   
Talk manoeuvres. No aerosol CFUs were recovered from either talk manoeuvres for 23/24 
(96%) participants and a single aerosol P. aeruginosa CFU was cultured from the remaining 
two participants (one masked and one unmasked study; Table 4.2). 
Face masks and cough etiquette manoeuvres. Of the 19 participants that produced culture 
positive aerosols during uncovered coughing, two (11%) produced P. aeruginosa positive 
aerosols wearing the surgical mask, and four (21%) grew P. aeruginosa in their aerosol cultures 
when wearing the N95 mask. In contrast, 68% of these participants (n=13) grew P. aeruginosa 
in their aerosols using cough etiquette.  
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Table 4.2. Number of participants with detectable aerosol P. aeruginosa colony forming unit (CFU) counts across each study manoeuvre* 
Manoeuvre 
 
Participants with 
detectable 
P. aeruginosa CFUs, 
n (%) 
Stratification of participants with detectable  
P. aeruginosa CFUs into high and low viable  
aerosol production   
  
         ˂10*                                               ≥10* 
Uncovered coughing (Reference) 
 
19 / 25 (76.0) 5 / 5 14 / 14 
Talking† 
 
1 / 24 (4.2) 0 / 5 1 / 13 
Talking wearing a surgical mask† 
 
1 / 24 (4.2) 0 / 5 1 / 13 
Coughing wearing a surgical mask 
 
2 / 25 (8.0) 0 / 5 2 / 14 
Coughing wearing an N95 mask‡ 
 
4 / 24 (16.7) 1 / 5 3 / 14 
Cough etiquette 
 
13 / 25 (52.0) 2 / 5 11 / 14 
 
*Participants were stratified according to a pre-defined definition of high (≥ 10 CFU) and low (<10 CFU) viable aerosol production of detectable 
P. aeruginosa CFU during the uncovered cough manoeuvre.  
†One participant did not complete the manoeuvre (insufficient culture media available) 
‡One participant did not complete the manoeuvre (due to adverse event) 
Definition of abbreviations: CFUs, colony forming units 
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High viable aerosol production (total CFUs 10) was observed in 14/19 (74%) participants 
who cultured at least one CFU in the uncovered cough manoeuvre. In these participants a 
reduction in aerosol P. aeruginosa concentration (log CFU) was demonstrated with each 
strategy designed to interrupt aerosol dispersal: surgical mask (-94%); N95 mask (-94%); 
cough etiquette (-53%).  The surgical mask (p<0.001) and the N95 mask (p<0.001) were both 
effective in reducing infectious airborne dispersal compared to uncovered coughing, with 
cough etiquette providing less reduction in mean P. aeruginosa CFUs than both masks (Table 
4.3).  
 
Table 4.3  Pseudomonas aeruginosa total colony-forming unit (CFU) counts for each of the 
manoeuvres compared to uncovered coughing (reference) for the high viable aerosol producers 
(n=14) 
 
*One participant did not complete the manoeuvre (insufficient culture media available) 
†One participant did not complete the manoeuvre (due to adverse event) 
Definition of abbreviations: CI, confidence interval; CFUs, colony forming units 
 
 
Manoeuvre Log10 P. aeruginosa CFUs 
 mean (95% CI)  
p value 
Uncovered coughing (reference) 
 
1.66 (1.41-1.91) - 
Talking* 
 
0.02 (0.00-0.07) <0.001 
Talking wearing a surgical mask* 
 
0.02 (0.00-0.07) <0.001 
Coughing wearing a surgical mask 
 
0.11 (0.00-0.32) <0.001 
Coughing wearing an N95 mask† 
 
0.13 (0.00-0.30) <0.001 
Cough etiquette 
 
0.90 (0.50-1.30) <0.001 
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4.4.4 Mask comfort 
Tolerability of the masks during cough manoeuvres varied, with 13 (54%) participants 
providing a higher comfort rating to the surgical mask than the N95 mask, compared with two 
(8%) who provided a higher comfort rating to the N95 mask and nine (38%) who had no 
preference (p=0.013) (Figure 4.2). Key comments regarding the masks by the participants 
included: a perceived restriction to or reduction in ease of breathing (n=15, [N95=12]), 
sensation of heat (n=9, [N95=6]), sensation of dampness (n=3, all surgical) and 
rubbing/pressure from the mask during coughing (n=2, [N95=1]).  
 
 
 
 
 
 
 
 
 
 
Figure 4.2  A matched pairs comparison of the comfort levels during cough manoeuvres while 
wearing the surgical mask and the N95 mask (n=24)  
Comfort level categories: a) very poor, b) poor, c) sufficient, d) good, e) very good. A low 
number of responses were obtained in the a) very poor and e) very good categories; therefore, 
for the analysis, the categories of a) very poor and b) poor were combined (“poor”), as were 
the categories of d) good and e) very good (“good”).   
The boxed area represents participants (n=9) who reported no preference for the comfort of the 
surgical mask or the N95 mask. Numbers to the right of the boxed area represent participants 
(n=2) who provided a higher comfort rating to the N95 mask and those to the left represent 
participants (n=13) who provided a higher comfort rating to the surgical mask. 
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 Poor Sufficient Good Total 
Poor  3 1 0 4 
Sufficient 11 2 1 14 
Good  0 2 4 6 
Total 14 5 5 24 
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4.4.5  Weight change in masks 
There was a similar change in weight of the surgical mask and the N95 mask (median 
(interquartile range) of 0.01 (0.00-0.02) grams and 0.02 (0.00-0.04) grams, respectively; 
p=0.23). Cough numbers for each manoeuvre were similar and there was no difference in the 
number of coughs during the N95 mask (p=0.15) and cough etiquette (p=0.52) tests compared 
to the uncovered coughing intervention (Table 4.4), indicating that fatigue or participant 
motivation were unlikely to have impacted the accuracy of the manoeuvres. 
4.4.6  Infection Control 
 P. aeruginosa or other CF pathogens were not cultured from blank aerosol tests or surface 
swabs of the tunnel. 
4.4.7  Adverse events 
 Overall, the manoeuvres were well tolerated; however, one participant (listed for lung 
transplant and FEV1 32.5% predicted) discontinued the N95 mask study due to claustrophobia 
and increased dyspnoea after mask application.  
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Table 4.4  Summary of the cough numbers for relevant interventions 
 
 
Uncovered coughing  
(Reference) 
(n=25) 
 
Coughing wearing 
a surgical mask 
(n=25) 
 
Coughing wearing 
a N95 mask 
(n=24) 
 
Cough etiquette 
 
(n=25) 
 
Number of coughs (mean (SD)) 78.7 (38.2) 74.6 (35.1) 75.3 (36.4) 77.0 (42.3) 
     
Mean (SD) difference in coughs from uncovered coughing  4.2 (9.6) 5.3 (17.7) 1.8 (13.3) 
 
p value 
 
 
0.04 
 
0.15 
 
0.52 
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4.5  Discussion 
This study demonstrates that at 2-metres from source, both surgical and N95 masks are highly 
effective in reducing aerosols containing viable P. aeruginosa in the droplet nuclei size range during 
voluntary coughing in people with CF. Our study uses a system that mimics a hospital environment 
and has several strengths; it was designed to reflect real-world occurrences by using a model that 
allows determination of air contamination at the recommended separation distance between people 
with CF and by investigating the effect of cough etiquette and two commonly available masks in 
hospitals on aerosol dispersal. The cough manoeuvres examined may also closely replicate aerosol 
production during airway clearance sessions and spirometry procedures. Furthermore, we provide 
much-needed information on the short-term tolerability (≤10 minutes) of mask wearing by persons 
with lung disease, which is an often-overlooked dimension of infection control.   
Cross-infection between people with CF has increasingly been reported over the past three decades, 
initially with Burkholderia cepacia complex (LiPuma et al. 1990; Govan et al. 1993), P. aeruginosa 
(Cheng et al. 1996; Jones et al. 2001; Kidd et al. 2013) and more recently Mycobacterium abscessus 
(Bryant et al. 2013; Bryant et al. 2016). Progressive changes to infection control policies have been 
implemented including cohort segregation and changes to practice for patients with CF in the clinic 
and inpatient facility. Airborne transmission of CF pathogens in aerosol droplet nuclei has been 
suggested and such evidence has contributed to the enhanced rigor of these policies (Jones et al. 2003; 
Wainwright et al. 2009). Increased separation distance between people with CF and the wearing of 
surgical masks during hospital visits are now recommended (Saiman et al. 2014). Evidence to support 
the effectiveness of the latter strategy has been limited. Two previous studies evaluated the effect of 
surgical mask wearing on bioaerosol spread within a CF cohort. Our finding of a strong protective 
effect with surgical masks during cough manoeuvres corroborate with and strengthen those of 
Driessche et al. who demonstrated an 86% reduction in environmental detection of airborne  
P. aeruginosa concentration during mask wearing compared to the reference (coughing without a 
surgical mask) in a controlled laboratory model (Driessche et al. 2015). In contrast, Zuckerman and 
colleagues found no difference in rates of air contamination of outpatient exam rooms between mask 
wearing and unmasked patients with CF, although the overall positive air sample yield was low, 
including in the control group without mask (0.7%) (Zuckerman et al. 2015).  
Three quarters of the participants that were studied produced aerosols containing viable P. aeruginosa 
at 2-metres during uncovered coughing. The only predictor of expired aerosol containing viable 
bacteria was the sputum load of P. aeruginosa, which agrees with the results of our earlier work 
(Knibbs et al. 2014), further suggesting burden of infection is a very important determinant of 
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potential infectiousness. A previous study using artificially generated aerosols demonstrated that  
P. aeruginosa respiratory samples with a mucoid phenotype exhibited improved survival, although 
this advantage did not extend to epidemic strains (Clifton et al. 2008). The aerosol samples from the 
uncovered cough manoeuvres in our study revealed both unique and shared Australian strains of  
P. aeruginosa, but the overall numbers were too small to make any conclusions regarding survival 
characteristics.  
To date, very few studies have directly compared the performance of various respiratory hygiene 
strategies in vivo and to our knowledge, this study is the first that investigates the outward protective 
effects of various interventions in a CF population with chronic P. aeruginosa infection. We 
demonstrated that surgical and N95 masks both significantly reduce the potential for bioaerosol 
dispersal with >90% reduction in the mean total CFUs. Previous evidence suggested that impaction 
of microbe-laden droplets directly onto an obstruction such as a hand or surgical mask during 
coughing limits the formation of airborne droplet nuclei (Riley 1974); our findings support this 
suggestion. Likewise, an earlier study also found that surgical and N95 masks were equally effective 
in interrupting aerosol transmission of influenza in nine patients (Johnson et al. 2009). A different 
study considered the impact of cough etiquette strategies (including the hand, a tissue, an arm) on 
preventing cough aerosols in healthy volunteers (Zayas et al. 2013). Similar to our findings, they 
reported that the expelled cough aerosol was not completely blocked by cough etiquette, therefore 
posing a potential risk for airborne transmission (Zayas et al. 2013). Importantly, the majority of 
viable aerosol detected during uncovered coughing in the current study was in the respirable size 
range (≤4.7um) and this was not significantly different for the cough etiquette manoeuvre.  
Our study also demonstrates that talking is a low infectious-aerosol producing activity, potentially 
indicating that the implementation of mask policies for people with CF within the hospital should 
especially target relevant high risk clinical settings. During times of known high aerosol producing 
activities (performing spirometry and airway clearance) in the clinical setting when a mask is not be 
feasible, then other considerations such as high air exchange rates, negative pressure rooms and/or 
adequate washout time periods between patients in individual rooms is important.  
Although short mask wear duration was overall well tolerated by people with CF, it was perceived as 
being less comfortable when compared with no mask for the participant, particularly the N95 mask 
where additional outward protection was not observed. This may be an important factor when 
considering adherence to correct wearing technique, especially over extended periods. In healthy 
subjects and healthcare professionals, the use of face masks has been associated with increased 
breathing resistance (Lee and Wang de 2011), headaches (Lim et al. 2006), and physical discomfort 
(MacIntyre et al. 2009; Radonovich et al. 2009), and tolerability lessens with increased duration of 
67 
 
wear (Shenal et al. 2012). Furthermore, the physiological effects and comfort of mask wear amongst 
people with respiratory conditions has not been studied extensively and may have adverse impact. 
One study that compared surgical and N95 mask efficacy in patients with confirmed influenza 
reported that one participant (from a cohort of 10) was unable to complete the short protocol due to 
respiratory distress (Johnson et al. 2009). However, Dharmadhikari and colleagues investigated the 
clinical efficacy of surgical masks over extended periods in patients with multi-drug resistant 
tuberculosis and demonstrated a 56% reduction in transmission risk. Patients wore surgical masks for 
up to 12-hours duration, with permitted interruptions for meals and medication, although it was 
reported that patients with respiratory distress were not enrolled into the study and incentives were 
used to encourage adherence (Dharmadhikari et al. 2012). The tolerability of mask wear in people 
with respiratory infection and lung disease is an area that requires further investigation. 
High rates of mask interference by the wearer have been reported in people with CF in the outpatient 
setting (Zuckerman et al. 2015). In our study, the participants were unable to touch or readjust the 
masks during the testing period, as the arms were positioned outside of the tunnel. However, mask 
movement and slippage during the coughing manoeuvres were observed for some participants. In 
fact, it was noted that three of the four participants who had detectable P. aeruginosa CFUs in the 
N95 mask cough manoeuvre experienced mask movement, which may have led to an ineffective 
facial seal and contributed to the release of viable aerosol.   
The participants in this study comprised an adult cohort with moderate to severe lung disease.  Based 
on earlier data demonstrating a strong correlation between P. aeruginosa sputum density and cough 
aerosol concentration (Wainwright et al. 2009; Knibbs et al. 2014), sputum-producing participants 
were enrolled as a robust means of assessing mask efficacy within the clinical setting. Our results, 
nevertheless, highlight the need for additional studies to determine the role and effectiveness of masks 
in CF paediatric populations, or for those with preserved lung function and/or those who rarely 
expectorate sputum. Despite this, there are some important caveats to consider: i) one participant in 
the current study did not produce a sputum sample and importantly, was one of the six participants 
who did not culture P. aeruginosa in their cough aerosol. However, our earlier data demonstrates 
non-productive patients can produce viable aerosols (Wainwright et al. 2009; Knibbs et al. 2014); ii) 
quantitative sputum microbiology is not routinely performed in most CF Centres serviced by clinical 
microbiology laboratories; iii) other clinical parameters do not predict viable aerosol production 
(Wainwright et al. 2009; Knibbs et al. 2014) and iv) the infective inoculum of P. aeruginosa (or other 
CF pathogens) is not known and therefore we cannot estimate the extent of infection risk for an 
individual following single (or for that matter multiple) exposure episodes to cough aerosols. Taken 
together, we suggest that a universal mask wearing approach across both adult and paediatric CF 
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Centres should be strongly considered to mitigate the risk of person-to-person spread of CF 
pathogens. 
Limitations of our study include that the application and check of mask fit by a health care 
professional and the short mask wearing duration of less than 10-minutes may not reflect the typical 
application in a clinical setting; therefore the study may overestimate the protective effect of face 
masks. Furthermore, the cough etiquette technique adopted by participants differed widely, which 
may impact the results but does allow a more real-world situation. The culture media used in the 
Andersen Cascade Impactors and incubation conditions were selective for non-fastidious, aerobic 
gram-negative bacteria and did not allow the investigation of cough aerosol viability of other CF 
pathogens such as H. influenzae, S. aureus and non-tuberculous mycobacteria. Whilst we focused 
specifically on P. aeruginosa in this study, our earlier work has demonstrated similar findings of 
viable aerosols of common CF pathogens (Wainwright et al. 2009; Knibbs et al. 2014), thus it is 
likely that the effectiveness of masks would generalize to other bacteria in people with CF. Finally, 
compared to the clinically stable patients, we observed a greater proportion of participants receiving 
intravenous antibiotics for pulmonary exacerbations that were low viable aerosol producers. 
However, the current study was not powered to examine the impact of clinical status (clinical stability 
versus pulmonary exacerbation) and antimicrobial therapies on viable aerosol production. Further 
studies are required to address this clinically important question.  
In conclusion, masks are a simple and relatively inexpensive method to effectively interrupt aerosol 
dispersal of P. aeruginosa in droplet nuclei generated during coughing in people with CF, with the 
surgical mask providing enhanced wearer comfort. These data support the USA CFF Infection 
Prevention and Control Guidelines for individuals with CF to wear a surgical mask to reduce 
environmental contamination and potential viable aerosol spread associated with coughing in 
communal areas of health facilities (Saiman et al. 2014). Cough etiquette reduces viable bacterial 
aerosols, but not to the same extent as masks. Future studies will assess whether mask application by 
the wearer and a longer duration of mask wear in a CF cohort impacts wearer tolerability and mask 
effectiveness. 
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Chapter 5: Overall Discussion and Thesis Conclusions. 
5.1  Introduction 
Cystic fibrosis is characterised by repeated pulmonary infections and progressive lung destruction.  
Many of the organisms responsible for infections in people with CF are ubiquitous in the 
environment, and this was previously considered the source of acquisition.  However, studies over 
the last 30 years have provided evidence that cross-infection may be an important pathway that 
infection may be acquired by individuals with CF.  Following the initial cases of person-to-person 
transmission, strategies have been implemented to minimise this risk including infection control 
measures and regular surveillance of cross-infection with techniques such as molecular typing.   
Epidemiological studies have demonstrated that acquisition of transmissible strains of Burkholderia 
cepacia complex and P. aeruginosa may be associated with poorer clinical outcomes. The 
mechanisms of transmission of pathogens in patients with CF remain poorly defined and therefore, 
increased knowledge of potential routes is required to successfully interrupt cross-infection. Whilst 
cross-infection events were previously considered a result of contact or droplet transmission, the 
airborne transmission pathway has recently been speculated as a possible route.  
The implementation of and updates to CF infection control guidelines have evolved in response to 
evidence of cross-infection within CF populations. These strategies aim to reduce person-to-person 
transmission of CF pathogens by segregation and cohorting in hospital facilities according to 
microbiological status, maintaining a minimum distance of 2-metres between patients, and most 
recently, the recommendation to wear a surgical face mask when in communal areas of healthcare 
facilities. 
This thesis includes three studies that have investigated the feasibility of aerosolisation of CF 
pathogens and strategies to mitigate aerosol dispersal during coughing. Through the use of validated 
aerosol sampling systems, my studies have demonstrated that all of the common CF organisms can 
be aerosolised by people with CF, thus highlighting the importance of infection control universal 
precautions for all people with CF. With my colleagues, I have provided data on the effectiveness of 
face masks, finding that they are a simple and effective method to reduce aerosol dispersal. The 
tolerability and comfort of mask wear has also been explored, which is an important aspect of 
consideration for a population that have respiratory disease.   
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5.2  General Aims and Chapter Summaries 
The work undertaken in this thesis was based on two broad aims. Firstly, to determine for which of 
the common CF pathogens aerosolisation during coughing was feasible and to describe their survival. 
To achieve this aim, participants with CF and chronic respiratory infection with non-P. aeruginosa 
bacteria underwent five cough manoeuvres in cough aerosol sampling equipment that measured 
viable particles over distance and time (Chapter 2).  An additional subset of patients with M. abscessus 
infection were investigated to determine the aerosolisation capabilities of this organism (Chapter 3).  
The second aim of this thesis was to investigate effective strategies to interrupt potential viable 
airborne transport.  In Chapter 4, adults with CF and chronic P. aeruginosa infection undertook 
interventions of cough etiquette and different face masks to determine the ability of each to reduce 
viable aerosol dissemination.   
5.3   Key Findings of this Thesis 
5.3.1  Cough aerosolisation of common CF pathogens 
This is the first study that has investigated the particle size distribution and survival of common CF 
pathogens (other than P. aeruginosa) aerosolised during coughing over distance and time.  Particle 
size is an important determinant of potential deposition sites within the human airways and has 
implications for infection control measures, based on droplet versus airborne transmission. 
The findings of Chapter 2 indicate that CF pathogens including A. xylosoxidans, S. maltophilia, 
Burkholderia cepacia species and S. aureus can be aerosolised during coughing and survive within 
droplet nuclei for extended periods up to 45-minutes and travel up to 4-metres from the source. 
Consistent with earlier reports, a positive correlation was found between the organism aerosol 
concentration and sputum bacterial load of GNB and S. aureus to that observed with P. aeruginosa 
(Wainwright et al. 2009; Knibbs et al. 2014).  This suggests those with higher quantitative sputum 
counts pose the greatest transmission risk and that some people may be “super-spreaders” of common 
CF pathogens. 
Our research group has now investigated the aerosol characteristics of P. aeruginosa (Knibbs et al. 
2014), these studied in Chapter 2, and M. abscessus in Chapter 3 (Bryant et al. 2016) and have 
demonstrated similar properties between all of these common CF pathogens. 
5.3.1.1  Limitations 
The infectious dose of each organism tested in Chapter 2 is unknown and therefore, whilst the in-vivo 
aerosolisation and survival of common CF pathogens from people with CF has been demonstrated, it 
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is not possible to quantify the risk of airborne transmission to an individual. Although strong evidence 
of cross-infection of CF pathogens exists in the literature, the exact route of transmission cannot be 
proven, with airborne transmission suggested after excluding the likelihood of close proximity contact 
and droplet transmission.    
The majority of participants enrolled into the study were adults, and therefore there may have been a 
bias towards those with more advanced lung disease and sputum producers. Therefore, the results 
may over-estimate the level of aerosol production in the broader CF population and future studies 
should address aerosolisation capabilities in younger people with CF and those who are non-
productive and/or those who have mild lung disease. Furthermore, voluntary coughing in this 
experimental setting may not directly reflect spontaneous coughing or that during airway clearance. 
5.3.1.2  Implications of Findings and Future work: 
Data presented in Chapter 2 has increased understanding of potential transmission pathways of CF 
pathogens. The findings have demonstrated that pathogens commonly isolated from respiratory 
samples in people with CF can be generated during coughing and persist as droplet nuclei for extended 
periods. Therefore, airborne transport is possible as the particle sizes of viable aerosols detected are 
capable of remaining suspended, moving with air currents associated with indoor ventilation and may 
have the potential to be inhaled by an individual to establish infection. This has implications for 
infection control policies and consideration should be given to use of face masks and ensuring 
adequate air exchange rates within clinic and communal areas housing people with CF to minimise 
the potential transmission risk. 
Notably, not all of the common CF pathogens have been implicated in epidemic outbreaks or cross-
infection. This suggests different transmission potential that varies between bacterial species, and 
highlights an area that requires future investigation.  Whilst people with non-CF lung disease may 
have chronic infection with similar organisms, limited epidemiological studies and molecular typing 
have demonstrated limited shared strain infection; it has yet to be determined if this is as a result of 
cross-infection or acquisition of common environmental strains. The potential for aerosolisation 
during coughing should be investigated in non-CF respiratory patient groups such as bronchiectasis 
and chronic obstructive pulmonary disease (COPD). 
Future studies to extend on the current work presented in Chapter 2 should include: 
- Aerosolisation abilities of a population of people with CF in the younger age group, those 
with  preserved lung function and/or are non-productive of sputum; 
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- Investigation of cough aerosolisation potential in people with non-CF respiratory disease and 
who have chronic bacterial (P. aeruginosa) infection. 
 
5.3.2  Cough aerosolisation of Mycobacterium abscessus  
Following on from Chapter 2, this study included three participants with chronic  
M. abscessus infection. This study has provided proof of concept that M. abscessus can be aerosolised 
during coughing and provided knowledge as to a potential transmission pathway of M. abscessus that 
was not previously considered likely.  The study also highlighted the extended survival of this 
organism, most likely as a fomite, which may have implications for cleaning procedures within 
hospital facilities. 
5.3.2.1  Limitations 
The study included a small number of participants.  This was due to an interruption to the testing after 
delayed positive isolate was detected, which was of uncertain origin. Consequently, there was 
insufficient data to perform statistical analyses, nor to determine if AFB smear status is a marker of 
likelihood of M. abscessus aerosolisation. 
5.3.2.2  Implications of Findings and Future work: 
The findings of this study have implications for infection control guidelines for people with CF and 
active M. abscessus infection. Firstly, it has provided evidence that M. abscessus can be aerosolised 
within particles of the respirable size range. This suggests that airborne transmission may be possible. 
The study has also demonstrated the extended ability of M. abscessus to survive ex-vivo. 
M. abscessus infection has been shown to have potential clinical detriment to people with CF, may 
exclude consideration of lung transplant and may require extensive therapies, many of which have 
toxic profiles; therefore it is paramount to minimise the risk of cross-infection.  Based on these 
findings, airborne precautions or measures to limit aerosol dissemination should be considered for 
CF Centres, in both the inpatient and outpatient setting.  These data suggest that people with CF and 
M. abscessus infection may need to be accommodated within hospital areas with rooms with negative 
pressure and/or adequate air exchange in both the inpatient and outpatient settings. Furthermore, 
additional cleaning methods are required to minimise environmental contamination. 
Infection with M. abscessus is also increasingly reported in the non-CF general respiratory population 
and therefore, the ability to generate viable aerosols should be tested in this group.  M. abscessus 
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resides in water supplies and the environment should be investigated as a possible source of strains 
that have been identified in clinical samples.   
Future studies to extend on the current work presented in Chapter 3 should include:  
- Studying a larger cohort of people with CF to confirm these findings and determine if there 
are any clinical variables that may predict the viable aerosol potential of an individual; 
- Exploring effective methods of decontamination for M. abscessus, such as UV-C irradiation;  
- Investigating other potential modes of acquisition of M. abscessus, especially environmental 
sources such as water supplies of hospital and homes of people with infection to assess the 
genetic relatedness of clinical and environmental samples; 
- Studies to confirm previous findings of potential aerosolisation of M. abscessus from showers 
and to compare strains with those found in patients with M. abscessus infection.  
 
5.3.3  Effectiveness of face masks and cough etiquette  
In Chapter 4, a study to investigate some of the readily available approaches within a hospital facility 
to interrupt outward aerosol dispersal during coughing in people with CF was described. The 
effectiveness of the surgical mask, the N95 mask and cough etiquette at reducing viable aerosol 
dispersal has been demonstrated and the tolerability of mask interventions assessed. 
5.3.3.1  Limitations  
As previously discussed, an adult cohort with CF was enrolled in this study. Overall the group had 
moderate lung disease with a chronic history of P. aeruginosa infection and all but one were 
productive of sputum. This selection bias may have resulted in a larger detectable aerosol 
concentration and therefore the results may not be representative for all people with CF. The study 
was undertaken with voluntary forced coughing and the numbers of manoeuvres performed may 
exceed what would be typical clinical setting over the same duration.  Furthermore, the masks were 
sized and fitted to the participants by health care professionals so as to ensure the correct application, 
and test the maximum, pure features of the ability of the mask to reduce aerosol dispersal.  
Consequently, this may not reflect mask wear in a clinical setting where an individual would typically 
be responsible for self-application. Taken together, these data may therefore overestimate the 
protective effect of masks in a real-world setting.   
Whilst the study explored the important aspects of tolerability and comfort associated with mask 
wearing, it did not investigate the psychological stigma of mask usage. Nor was the study able to 
assess how often a wearer may interfere with the mask because the participants’ arms were placed 
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outside of the Distance Rig to prevent touching and readjustment. Both of these factors may impact 
overall adherence and effectiveness of mask wearing in a typical clinical setting. 
The study investigated the outward protection offered by a face mask in preventing environmental 
contamination. An important characteristic of face masks is also the inward protection to the wearer 
from external pathogens.  This study was unable to investigate this feature and such studies, although 
important, are difficult to design and undertake because of ethical considerations in exposing human 
subjects to bacteria. 
5.3.3.2  Implications of findings and future work: 
The study highlighted a number of findings that are important in the clinical care of people with CF.  
Firstly, the study demonstrated that face masks available within a health-care facility are effective in 
reducing the dispersal of viable cough aerosols in people with CF, and therefore supports the recent 
updates to the CF Foundation infection control guidelines to wear a mask to reduce risk of 
transmission in communal areas (Saiman et al. 2014). People with CF rated the surgical mask more 
comfortable than the N95 mask, which may be important when considering adherence. Cough 
etiquette was also shown to reduce aerosol dispersal, which provides an alternative strategy (with 
hand hygiene) for when a mask may not be available. 
An area of future work arising from these studies could investigate the effectiveness of mask in 
different cohorts including: a younger population with CF; those with mild lung disease and/or 
preserved lung function and non-sputum producers.   Additionally, a longer wear time of mask that 
resembles a typical clinical application should be explored to assess if moisture saturation from 
expiration and coughing impacts effectiveness. Various face masks commercially are also now 
available and some promote features of: aesthetic appeal through vibrant colours and adorning 
pictures targeted towards a paediatric group; greater tolerance and comfort through use of different 
manufacturing materials; long-term re-use and laundering of individual masks. With the 
implementation of mask wearing policies in many CF Centres worldwide, patients may consider 
purchase of these. Commercially available masks should be evaluated in future studies to ensure they 
provide the same level of effectiveness.  
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5.4   Summary of Future Work 
Future studies to be undertaken ensuing from the findings presented in this thesis will include: 
 i) To determine if individuals with non-CF related lung infection are capable of  
  producing infectious aerosols during coughing; 
 ii) To assess the effect of UV-C irradiation in eliminating aerosols containing  
  M. abscessus; 
 iii)  To determine potential environmental sources of M. abscessus; 
 iv) To determine the effectiveness of hospital and commercially available masks in  
  a paediatric cohort; 
 v) To determine the effectiveness of masks in reducing aerosol dispersal worn for  
  clinically-relevant times. 
5.5  Concluding remarks 
This thesis has provided novel data regarding the generation and survival of aerosolised CF pathogens 
during coughing from people with CF. It has demonstrated the effectiveness of readily available 
mitigation strategies and explored the patient perspective of tolerability and comfort of wearing face 
masks.  The findings have provided increased understanding of potential transmission pathways of 
CF pathogens and strategies to interrupt aerosol dispersal. Finally, it is hoped that this newly acquired 
knowledge will assist in refining infection control guidelines to further protect people with CF from 
acquisition and transmission of pathogens. 
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